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The Role of Acute Nomnovolaemic Haemodilution in Gastro-intestinal Surgery 
By Grant Sanders 
Background: 
Allogeneic transfusion confers a risk to the recipient and the recent introduction of 
leucocyte depleted blood has increased cost pressure on health resources. 
Colorectal surgery is a high blood usage field with 43% of all patients in our unit 
being transfused, over a three year period. 
Patient perceptions: 
Despite the risks associated with transfusion, a majority of patients are willing to 
have an allogeneic transfusion (85%) and think it is safe (89%), which may have 
implications in the uptake of alternatives available. 
The effect of bowel preparation 
Picolax bowel preparation causes significant dehydrating effects which may impair 
acute normovolaemic haemodilution (ANH). These effects can be minimised by 
administering intravenous normal saline. 
Acute normovoiaemic haemodilution (ANH) 
ANH significantly reduced allogeneic transfusion rate from 39% to 15% in the pilot 
study, however the controls were historical. No reduction in transfusion rate was 
seen (29% and 30%) in the prospective randomised controlled trial (n=160). Pre­
operative haemoglobin, blood loss, age, and transfusion protocol were the key 
factors influencing transfusion. 
The effect of ANH on coagulation 
ANH causes hypocoagulation, and this may explain why the expected red cell 
saving, as shown by mathematical modelling, was not seen in patients 
haemodiluted compared with controls. 3 
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Chapter 1: Introduction and Aims 
Blood transfusions are often given to surgical patients and allogeneic transfusion 
in this setting confers a risk to the recipient in tenns of immunomodulation, 
transmission of disease, allergic reaction, and alloimmunisation. More recently, the 
introduction of leucodepleted blood has led to an increased cost pressure on 
health resources. Awareness of the adverse effects of allogeneic blood transfusion 
has prompted both physicians and patients to search for alternatives to the use of 
perioperative donor blood. 
There are essentially three techniques of autologous transfusion: 
a) Predeposit: If surgery is urgent and required within 2 weeks of diagnosis, 
predonation Is impractical. In patients requiring gastrointestinal surgery the ability 
to absorb nutrients such as iron is often compromised, making preoperative 
donation of little value. 
b) Red cell salvage + reinfusion: This technique is not applicable in abdominal 
surgery when the bowel is open or in surgery for malignancy. 
c) Haemodilution: Acute normovolaemic haemodilution (ANH) entails removal of 
blood from a patient immediately before or shortly after induction of anaesthesia 
and simultaneous replacement with cell free fluid. By using this procedure prior to 
intraoperative blood loss, fresh autologous blood is made available for later 
transfusion. As a result of haemodilution blood subsequently lost contains 
proportionally fewer red blood cells per millilitre, thus minimising intraoperative 
loss of autologous red cells. 
Although the indications and exclusion criteria for ANH have been described, the 
efficacy of ANH is inconclusive and will remain so until well designed trials are 
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completed. Furthermore, the effect of ANH on coagulation Is currently unknown. If 
ANH proves successful In decreasing the units of allogeneic blood transfused, 
there would be important psychosocial and health economic consequences. 
Aims of This Study: 
Define the role of haemodilution in gastrointestinal surgery in terms of: 
1) reduction in allogeneic blood usage and its potential as a blood saving 
technique, 
2) clinical outcomes and hospital stay, 
3) the effect on coagulation, 
4) identify patient preferences towards blood transfusion and haemodilution. 
16 
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Chapter 2: The Risks Of Allogeneic Transfusion 
Allogeneic transfusion confers a risk to the recipient in terms of 
immunomoduiation, transmission of disease, allergic reaction, and 
alloimmunisation. In some regions blood is in short supply. Elective surgery is 
occasionally cancelled in Canadian cities because of a lack of available blood and 
a shortfall of four million units of red cells is projected in the United States by 2030 
if the present rate of RBC utilization continues^ It is likely that blood will become 
scarcer with increasing population age and the increased number of donors 
excluded^. Every transfusion decision should therefore have a risk/benefit 
assessnrient^, but what are these risks? 
Immunomoduiation 
In the 1970's the transfusion of allogeneic blood was demonstrated to suppress 
the immune responses of human hosts to renal allografts'*. Since then, over 100 
observational and clinical studies have examined the immunosuppressive effects 
occurring with perioperative allogeneic transfusion. 
The difficulty is that studies comparing outcomes in transfused versus non-
transfused neglect confounding factors; largely the reason for transfusion. Even 
the studies that adjust for the severity of the principal diagnosis often fail to adjust 
for the presence and severity of co-morbidities (diabetes mellitus, congestive heart 
disease, lung disease, liver disease or kidney failure), and these may be a more 
important determinant of post-operative infection. Furthermore, the number of 
patient days with an indwelling urinary catheter may be the most important 
detemninant of whether a patient develops a postoperative urinary tract infection. 
It would be unethical to transfuse or not for the purposes of a study. Therefore 
randomised studies to date have compared the risk of cancer recurrence and/or 
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post-operative infection between a treatment arm receiving standard or buffy coat 
reduced red blood cells (RBCs) or whole blood, and a control ami receiving 
autologous or leucodepleted RBCs or whole blood. The number of leucocytes 
present in buffy coat depleted packed cells is about 30% of whole blood, 
compared with 0.1% present in leucocyte depleted blood^. These studies are 
based on the assumption that the transfusion of autologous or leucodepleted 
RBCs, or whole blood, is immunologically neutral, since transfusion associated 
immunomoduiation (TRIM^) has been attributed for the most part to 
immunologically active white blood cells''-®, although others have proposed 
allogeneic plasma^'^°. Although It is known that allogeneic transfusion impairs T-
cell mediated immunoresponse, as measured by a decrease in antigen-driven 
lymphoblastic transformation and natural killer activity^\ attributing this as the 
cause is less certain^^. 
Randomised Controlled Trials 
Houbiers et al^ randomised patients to receive either buffy coat depleted or 
leucocyte depleted red cells in a study of 697 patients operated on for colorectal 
cancer. They found no difference between the 2 groups in survival, disease free 
survival, cancer recurrence rates, or overall infection rates after an average follow 
up of 36 months. However, those patients who had a curative resection and 
received a transfusion of any sort had a lower 3 year survival and higher infection 
rate. They went on to publish two further papers. One illustrated a dose response 
relationship between units transfuse,d and infection rates'*^: the corrected relative 
risk was 1.6 for 1-3 units of red cells and 3.6 for more than 3 units. The second 
looked at 5 year survival and cancer recurrence rates^"*. They again found no 
difference between groups, but did find a significant reduction in survival between 
transfused and non-transfused. There was however no difference in cancer 
18 
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recurrence rates between transfused and non-transfused. They concluded that 
transfusion of leucocyte depleted blood in the perioperative period has no effect on 
long term survival and/or cancer recurrence. 
Two randomised controlled trials have tested this hypothesis using autologous 
blood; Busch et aP^ studied 475 colorectal patients with pre-operative donation 
(POD) the autologous technique. 2 units were donated and transfusion could only 
take place if >500ml was lost Intra-operatively or the haemoglobin fell to <10.5 
g/dl. They found no difference in mortality, infectious complications or disease free 
survival over a median "2.5 year follow up. However the disease free survival was 
significantly greater in patients who received no transfusion. They concluded that it 
is the circumstances necessitating transfusion rather than transfusion itself that 
are the real detemninants. Heiss et al^^ studied 120 colorectal patients and also 
used POD as the autologous technique. Transfusion was recommended if the 
haemoglobin fell to <10 g/dl. They found no reduction in cancer recurrence with 
autologous transfusion, however a significantly greater percentage of patients in 
the allogeneic arm had Infectious complications (27% versus 12%). In addition, the 
infection rate increased with the number of units transfused. There was however a 
design problem with both of these studies. In both studies, as a result of POD 
patients presented to the operating theatre with a lower haematocrit than patients 
from the allogeneic transfusion arm. In addition, if the POD patients required a 
transfusion of more than the 2 units pre-deposited, they were given allogeneic 
RBCs. As a result, in the study by Busch et al, 75% of patients in the POD arm 
received a transfusion, 28% receiving further allogeneic blood. This compared with 
56% of patients in the allogeneic amn being transfused. In the study by Heiss et al, 
91% of patients in the POD arm received a transfusion, 35% receiving further 
allogeneic blood. This compared with 60% of patients in the allogeneic arm being 
transfused. 
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Tartter et a r studied 221 patients undergoing gastrointestinal surgery randomised 
to receive packed RBCs or leucocyte depleted cells. They found a significantly 
greater percentage of patients in the allogeneic arm had infectious complications 
(44% versus 16%). However there were significantly more patients with ulcerative 
colitis In the allogeneic group (26 versus 5), which could have affected the results. 
The 2 papers with the most dramatic results, illustrating an adverse effect of non-
leucocyte depleted blood in colorectal surgery, were by Jensen et aP®'""^ . In the 
first, they compared patients transfused with whole blood or leucocyte depleted. 
53% of patients received a transfusion, with infectious complications occurring in 
27% of those transfused with whole blood and 2% of those transfused with 
leucocyte depleted blood. In the second, they compared patients transfused with 
buffy coat poor blood or leucocyte depleted blood. 44% of patients received a 
transfusion of which surgical infectious complications occurred in 18% and 0% 
respectively. Non-surgical infectious complications (pneumonia, urinary tract 
infection) occurred in 37% and 14% respectively. 
The most stringent study to date was that by Van de Watering et aP° who 
randomised 914 patients scheduled for cardiac surgery to one of 3 treatment 
arms: buffy coat reduced allogeneic RBCs; WBC reduced allogeneic RBCs filtered 
before storage; and WBC reduced allogeneic RBCs filtered after storage. They 
found no significant difference in the Incidence of post-operative infection in the 3 
arms. However, when the pre and post storage arms were combined, recipients of 
buffy coat depleted RBCs had a higher incidence of post-operative infection, but 
the result was not significant (p=0.06). Interestingly, they also detected an 
unexpected association between WBC-containing allogeneic blood transfusion 
and mortality form other causes other than post-operative infection (7.8% and 
3.6% respectively, p=0.015). When analysed further, they found that this 
difference was only significant when patients received 4 or more units of blood. 
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They postulated that their study was more likely than previous randomised 
controlled trials to detect differences because of the substantially higher 
transfusion dose in this group of patients (only 5.2% of these cardiac patients 
received no transfusion). However, this association may have limited applicability 
because data obtained from patients undergoing cardiac surgery may not be 
generalizable to other clinical settings. The extracorporeal circuit used in cardiac 
surgery induces a diffuse Inflammatory response that may predispose to 
postoperative infection or other surgical complications. 
The mechanism behind the association between WBC-containing allogeneic 
transfusion and increased post-operative mortality is unclear. Hebert et a l^ \ also 
unexpectedly, reported that a restrictive strategy of allogeneic transfusion may be 
superior to a liberal transfusion strategy in critically ill patients with normovolaemia. 
It is clear that more research is needed to elucidate the possible biologic 
mechanisms that may underlie such other adverse effects of allogeneic 
transfusion. 
Table 2.1, below, was derived from the 7 randomised studies to date and 
summarises the percentage infection rates in the 3 groups of patients receiving no 
transfusion, leucocyte depleted or autologous blood (control) or allogeneic / buffy 
coat reduced blood (treatment). 4 studies show a significant increase in infectious 
complications in the treatment arm, 1 shows a non-significant increase (p=0.06) 
and 2 show no increase. 
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Author Total 
sample 
size 
Overall % 
Transfused 
infection % 
Not 
Transfused 
Control Treatment 
Jensen^** 
(Colorectal) 
197 53 2 2 * 23 * t 
Busch''' 
(Colorectal) 
475 65 27** 25 * 
Helss''^ 
(Colorectal) 
120 75 7 12** 27 **t 
Jensen'" 
(Colorectal) 
589 44 1 surgical 0 * 18 * * t 
7 other 14* 37 **t 
Houbiers'' 
(Colorectal) 
697 64 24 *42 **36 
Tartter'' 
(Gastrointestinal) 
221 27 . 11 16* 44** t 
Van de 
Watering^" 
(Cardiac) 
914 95 17* 23** 
Control: *Leucocyte depleted 
**Autologous (POD) 
Treatment: *Allogeneic whole blood / packed cells 
**Buffy coat reduced RBCs 
t significant difference between control and treatment arnris (p<0.05) 
Table 2.1: Summary of infection rates in published randomised controlled trials 
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Meta-analyses 
A meta-analysis conducted by Duffy et aP^ looked at post-operative infection rates 
in patients receiving autologous and allogeneic blood. They identified 7 suitable 
studies, 6 using pre-deposit and 1 cell salvage, giving a study population of over 
1000. The pooled odds ratio was 2.34 (95% confidence interval 1.6-3.5), however 
5 of these studies were retrospective. 
A meta-analysis of 3 randomised trials looking at cancer recurrence^^ showed no 
transfusion effect on cancer recurrence; the power however would only detect an 
effect of greater than 33% increase. 
The largest meta-analysis, published in 1998 '^*, included data from 6 randomised 
clinical trials with leucocyte depleted or autologous blood In the control arm (5 of 
which are discussed above) and 2 prospective cohort studies. They found no 
allogeneic transfusion effect on mortality or cancer recurrence; 3 randomised 
studies demonstrated an increased risk of post-operative infection in patients 
receiving allogeneic blood^ -^''®'''^ , the other 3 did not^ -''^  Two of the randomised 
studies were by the same author and were felt to be sufficiently different from the 
others in terms of patient mix and study design to be excluded from the final 
combined analysis, which revealed no difference between groups. However the 
power was such that only a 20% difference would be detected. 
Summary of immunomoduiation 
Observational studies comparing patients with and without transfusion almost 
unifonnly support the hypothesis of an increased risk of post-operative infection in 
the transfused group. A possible explanation for the disagreement in randomised 
controlled trials may be the adverse effects of TRIM are small (5-10%). Vamvakas 
and Blajchman^^ illustrated that a study population of 20000 patients would be 
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required if the overall infection rate in the entire study population was 
approximately 20% and almost half of the enrolled patients did not receive a 
transfusion. They concluded that definitive evidence regarding the existence of a 
deleterious immunomodulatory effect of allogeneic blood transfusion does not 
exist, but the available data does justify a high degree of suspicion. Similar views 
were expressed in a publication in the European Journal of Cancer^^ Despite this, 
the signatories of a letter published in Transfusion felt that there was still no 
evidence to support universal WBC reduction^®. These views were echoed at the 
state of the art conference on TRIM^^. 
The implementation of universal white cell reduction will preclude the undertaking 
of further randomised trials investigating TRIM effects mediated by allogeneic 
WBC's. It has been suggested that a meta-analysis of the raw patient data may be 
able to explain discrepancies and answer the question^^. Until then, the long 
standing hypothesis of the potentially deleterious immunomodulatory effect of 
perioperative allogeneic transfusion remains unresolved. 
Transmission of Disease 
A recent survey has shown that the risks of blood screened by the Australian Red 
Cross Blood Service being infective for HIV or hepatitis B or C viruses are 0.79, 
2.71 and 4.27 respectively per million donations^". Slightly higher rates of HIV 
transmission have been reported in Canada^\ Between 1991 and 1993 in the 
USA, the risk of blood screened being infectious for HIV or hepatitis B or C were 
2.03, 15.87 and 9.71 respectively per million donations. This gave an aggregate 
risk of 1:34000. Since then, screening tests have been introduced that lessen the 
risk by 27 to 72%^^. In a follow up study of recipients of 20,000 units of blood 
transfused in 22 North London hospitals, no transfusion transmitted infections 
were identified in blood samples taken 9 months post transfusion^^. In the UK, the 
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risk of transmission of Hep B, Hep C, and HIV Is 1 in 100,000 to 400,000, 1 in 
3,000,000 and 1 in 4,000,000 respectively (adapted from British Committee for 
Standards in Haematology 2001)^'*. 
There is no doubt that the risks in developed countries are smalP^'^^; in third world 
countries they exist to much greater degree. Although there is no evidence of 
vCJD transmission in humans, concern has been provoked by a study in which 
one of 10 asymptomatic sheep, 318 days after being given 5g of cow brain 
infected with BSE in their feed, seemed to transmit BSE to a second sheep via a 
400ml blood transfusion^ '^^ ®. The recent introduction of leucocyte depleted blood 
has decreased the potential spread of CMV, HTLV1/11, EBV as well as vCJD -^®. 
Allergic Reaction And Wrong Blood To Patient 
Non-haemolytic reactions occur in 1-5% of RBC transfusions. They are due to 
interleukins and antibodies reacting with transfused plasma proteins and allergens. 
Haemolytic transfusion reactions are rare with current methods of cross matching 
but continue to occur in the range of 1:24,000. Resultant fatality is in the range of 1 
in 250,000 to 1 in a million transfusions^^. 
Analysis of the first 2 annual reports from the SHOT (serious hazards of 
transfusion) initiative between 1996 and 1998, revealed that 52% (191) of the 366 
cases reported were "wrong blood to patient". There were 22 deaths from all 
causes, 3 from ABO incompatibility. The denominator, however, is not known. In 
the report 2000-2001 there were a total of 213 incidents of "wrong blood" Including 
3 deaths, indicating an increase from previous years. 
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Conclusions 
In conclusion, allogeneic transfusion does carry risks. The recent introduction of 
leucocyte depleted blood has led to an increased cost pressure on health 
resources. This decision was based on the hypotheses that this practice would 1) 
prevent the theoretical risk of transmission by transfusion of the agent of variant 
Creutzfeldt-Jacob disease (vCJD)'''°"'*°, 2) enhance overall transfusion safety by 
reducing the deleterious immunomodulatory effects'*" and prevalence and severity 
of febrile transfusion reactions^. 
If an alternative could be found, one cardinal benefit not mentioned previously, is 
the peace of mind associated with receiving blood free from contamination, in 
particular, with HIV, hepatitis viruses and CJD. Slovic'*^ demonstrated that people 
tend to overestimate "unknown risks" and "dread risks". He defines "unknown 
risks" as those with delayed effects and new and unfamiliar risks. "Dread risks" are 
those over which we have no control and those that may have catastrophic 
consequences. Many patients perceive the risk of HIV in exactly these terms, 
despite reassuring statistics regarding the transmission of HIV by transfusion. The 
peace of mind that comes from having control over the risk of HIV and other 
potentially harmful effects of transfusion Is immeasurable, but nonetheless 
important to the patient undergoing surgery'*^. 
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Chapters: Methods of Avoiding Allogeneic Transfusion 
A number of methods have been utilised over the years in an attempt to decrease 
the use of allogeneic blood. These include meticulous surgical technique, 
transfusion trigger, autologous transfusion (preoperative donation, acute 
normovolaemic haemodilution, cell salvage, postoperative blood recovery), 
hypervolaemic haemodilution, controlled hypotension, erythropoietin, aprotonin, 
and oxygen carrying solutions. 
Surgical Technique 
The utilisation of good surgical technique which minimises blood loss and 
recognises the importance of efforts to limit the use of blood to clinical necessity 
has been emphasised on many occasions'*^. 
Transfusion Trigger 
Guidelines from both the Canadian Medical Association and the American Society 
of Anaesthesiologlsts suggest that a red cell transfusion is rarely indicated if the 
Hb Is > 10 g/dl and usually indicated if the Hb < 6g/dl in clinically stable patients 
not at risk of coronary artery disease"*^. 
The recent TRICC study^^ (Transfusion Requirements in Critical Care) 
demonstrated that a restrictive red blood cell transfusion strategy (maintaining 
haemoglobin between 7 g/dl and 9 g/dl) appears to be at least as effective and 
possibly beneficial in certain subgroups. The overall 30 day mortality was lower in 
the restrictive strategy group (18.7 % versus 23.3%, p=0.11). However, in patients 
who were less acutely ill (with an Acute Physiology and Chronic Health Evaluation 
11 score of <20), the 30 day mortality was 8.7% in the restrictive strategy and 
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16.1% In the liberal strategy arm (p=0.03). Among those less than 55 years of age, 
the 30 day mortality was 5.7% with the restrictive strategy and 13.0% with the 
liberal strategy (p=0.02); this did not apply to those with clinically significant 
cardiac disease. In addition, the mortality rate during hospitalisation was 
significantly lower in the restrictive strategy group (22.2% versus 28.1%, p=0.05). 
Jehovah's witness patients'*^ and haemodilution studies have also provided insight 
into the critical haemoglobin for patients. Conscious healthy adults have been 
shown to have no evidence of inadequate systemic oxygenation at haemoglobin 
concentrations of 4.5 to 5.0 g/df^. 
There is, however, no clear and specific haemoglobin (Hb) below which patients 
require a transfusion. The decision should be based on age, co-morbidity and vital 
signs in addition to Hb. 
In one study, the mere introduction of transfusion guidelines decreased allogeneic 
transfusion by 43% in elective surgical patients'*^. 
Autologous Transfusion 
Autologous transfusion is a term used to describe any procedure whereby 
previously donated (or shed) blood is transfused into the patient. In the 1990's, 
following substantial improvements in the safety of allogeneic blood, the emphasis 
has shifted from an effort to eliminate allogeneic transfusion to an objective 
evaluation of the benefits derived from autologous transfusion. A cardinal benefit 
difficult to quantify Is the "peace of mind" associated with knowing that they are 
receiving blood free from contamination with HIV or a hepatitis virus'*^. In addition 
there may also be unknown transfusion transmitted diseases. 
A survey was performed recently looking at the use of alternatives to allogeneic 
transfusion in Australian hospitals'*®. POD was most widely used (70% of 
hospitals), followed by cell salvage (27%) and ANH (24%). In contrast 
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antifibrinolytic drugs, desmopressin and erytliropoietin were used in fewer than 
10% of hospitals. The use was greatest in larger hospitals and teaching hospitals, 
with orthopaedics and cardiothoracic surgery reporting the highest usage. A high 
proportion of respondents indicated that ANH and POD should be used more 
often, endorsement for cell salvage being not as high. Interestingly perceptions 
that the three technologies are cost effective and have few side effects were 
common reasons for advocating higher use. 
Mercurlali et al'*^ have proposed a personalised approach to utilise all the methods 
available to obtain autologous blood and avoid the use of allogeneic blood. This 
approach takes into account the predicted blood loss (determined through a 
constantly updated retrospective analysis) minus the blood loss that patient can 
tolerate. 
Predicted red cell loss = Circulating red cell volume reduction from pre-surgery to 
post-surgery day 5 + RBC volume transfused: 
Red cell loss (ml) = EBV * (Hcto - Hcts) + ml of RBC transfused 
The blood loss the patient can tolerate = volume of red cell loss to maintain an 
accepted minimal haematocrit value: 
Tolerated RBC loss (ml) = (EBV * Hctbaseime) - (EBV * Hctminimum) 
The difference between the predicted and tolerated blood loss is the transfusion 
requirement of the individual patient expressed in ml of pure RBC (180-200ml 
RBC/unit^°, 250ml RBC/unit^\ or 300ml RBC/unit^l 
This estimate can then be used to determine the transfusion strategy to be 
adopted, having estimated the net gain of RBC for each strategy. 
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Pre-Operative Donation 
Units of blood are venesected prior to surgery and stored for up to 35 or 42 days 
depending on the anticoagulant / preservative solution used. POD only applies if 
the need for blood can be anticipated and a donation plan developed^^. The last 
unit is drawn no fewer than 72 hours before surgery, because a 72 hour interval is 
an estimate of the time needed to compensate for the acute volume and protein 
deficit caused by a one unit phlebectomy. Iron supplementation should begin as 
soon as surgery Is scheduled, usually 300mg of ferrous sulphate three times a 
day. The minimal level for autologous donation is 11 g/dl, and most patients can 
make 2 or 3 donations before this level is reached. 
The volume of blood a patient can deposit is a function of the total baseline 
circulating volume of RBC and the rate of recovery of RBC collected at each 
donation. Each unit of autologous blood collected (350-450ml), decreases 
haemoglobin by Ig/dl and haematocrlt(hct) by 3 points'*^'^. If insufficient time is 
given to the patient to compensate for the red cell losses, pre-donation offers very 
little advantage. Candidates for THR, in optimal clinical and haematological 
condition (Hb>13.5 g/dl, Hct>40%), donating 3 units over a 10 day period with 
intravenous iron administration after each donation, took 15 to 22 days to restore 
the quota of RBC lost with the first collection'*^. Another study demonstrated that 
collecting a total of 3 units, with collections every 3 days resulted in no greater 
RBC production than collections every 7 days'*^. 
Exclusions / risks - The donation: 
The only group of patients who must be excluded from donating according to the 
American Association of Blood Banks(AABB) Standards are those with significant 
bacterial infections or any potential for bacteraemia. Some Gram negative bacteria 
(Yersinia enterocolitica, Pseudomonas species, Citrobacter species ) can multiply 
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and produce toxins in blood stored In the refrigerator, without causing haemolysis 
or any usually detectable change in the appearance of the unit. 
Candidates are therefore those who are in relatively good health who can tolerate 
venesection and iron supplementation. A fatality risk of 1 per 101000 units 
collected would negate all life expectance benefits attributed to POD^^. High risk 
donors include patients with coronary artery disease, congestive cardiac failure, 
medication inhibiting the compensatory mechanisms of the cardiovascular system 
to the withdrawal of blood, aortic stenosis, transient ischaemic attacks and marked 
hypertension. A study by Popovsky et al^ ® reported that one in 16783 units 
donated was associated with an adverse event requiring hospitalisation; that is 12 
times as high as seen in volunteer blood donors. 
Exclusions / risks - The Transfusion: 
Transfusion of pre-donated autologous blood Is not without risk. In a retrospective 
review, adverse reactions to autologous blood composed 2.1% of all transfusion 
reactions reported and involved 0.16% (15/9353) of all POD red cells^^, although 
on further review only 60% were thought to be directly related to the autologous 
units. Complications include haemolysis of the unit during processing and storage 
resulting in haemoglobinaemia and haemoglobinuria if transfused, endotoxic 
shock if contaminated with gram negative bacteria, febrile non haemolytic 
transfusion reactions due to the release of pro-inflammatory cytokines from white 
blood cells in the refrigerator if storage is prolonged, and transfusion of the wrong 
unit. This last error - the administration of autologous blood to an unintended 
recipient - is of greatest concern. Random misadministration carries a 36% 
probability that the blood will be ABO incompatible^® and 5% of ABO incompatible 
transfusions have been reported as resulting in fatal acute haemolytic transfusion 
reactions^®. In these situations, the index of suspicion for a haemolytic reaction 
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may be low as the patient Is receiving blood thought to be their own, thus delaying 
intervention resulting in an even greater risk of adverse outcome. In addition, the 
misadministration of autologous blood carries with it an increased risk of Infectious 
disease transmission because some hospitals do not test autologous blood 
donors, and those that do, often accept donors who test positive for one or more 
markers. A recent report describing POD in Canada found an overall error rate of 
1 of 149 units to 1 of 322 units^^. Most of these were however administrative (late 
receipt of a unit at hospital or administration of allogeneic blood when POD blood 
was available). A prospective study by the Belgium SANGUIS group found that 3 
of 55 patients with autologous blood available received allogeneic instead®". 0.9% 
of responders to a 1992 College of American Pathologists survey indicated that 
they had issued autologous blood to the wrong patient on at least one occasion in 
the previous year^''. 0.5% reported that units collected from autologous donors had 
been transfused to the wrong patients on one or more occasions. A 1994 
American Association of Blood Banks survey reported that 1.2% of respondents 
indicated errors involving the transfusion of autologous blood to other patients 
during the previous year. Although actual error rates are not reported, another 
study reported an error rate of 1 per 68,000 mlsadminlstrations^®. In the United 
States 1 of 560,000 autologous units transfused resulted in a fatality due to ABO 
incompatibility®^. 
inclusion Criteria: 
Eiiglblllty based on blood loss is controversial. Vamvakas et al®® say blood loss 
should exceed 500-1000ml In at least 5-10% of cases. However a British 
consensus conference on autologous transfusion stated that POD should be 
considered only if the likelihood of per-operative transfusion exceeds 50%® ,^ in 
view of expense. 
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Blood losses are however difficult to predict^''^^ despite attempts to stratify 
patients pre-operatively®®^®. 
Efficacy: 
In 1992 1 in every 12 units of blood collected in the United States was the result of 
an autologous donation®^ This rate has declined with the re-evaluation of POD. Of 
129 patients undergoing elective colorectal cancer surgery over a 2 year period, 
only 28 were suitable for autologous donation®®. 
Within the NHS, a current disadvantage Is the difficulty of guaranteeing non-
cancellation of routine surgery. 
POD Induced Anaemia: 
The degree of anaemia induced by each unit of POD depends upon the extent of 
compensatory erythropoiesis and the interval between donations. Three authors 
reported no compensatory erythropoiesis in patients scheduled for hysterectomy®'' 
and radical prostatectomy®®"®^ whereas another reported that 60% of RBC's lost by 
weekly donations over a three week period were replenished^". Only with 
aggressive autologous blood phlebectomy (defined as a goal of 6 units donated 
over 3 weeks) does the net red cell volume expansion stimulated by the 
endogenous erythropoietin response to anaemia exceed the equivalent of 1 unit of 
allogeneic blood^\ The use of erythropoietin coupled with iron supplementation 
may improve this^^, although no clinical benefit has been demonstrated''®'^ '*. Given 
that the normal person takes many weeks to regenerate the blood lost in donation 
and that a lower haemoglobin level at admission is associated with an increased 
likelihood of transfusion, it is prudent to maximise the time between last donation 
and date of surgery®^ 
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Mathematical Model: 
A mathematical model, with a perioperative threshold haematocrit of 25%, applied 
to a 70kg patient with a blood volume of 5000ml and Initial haematocrit of 45% 
who had donated 2-4 units of blood pre-operatively, proved that POD could 
actually be hamriful to the patient^ ®. This occurs based on the assumption that with 
each unit donated, compensatory erythropoiesis resulted in replacement of 2/3 of 
the removed unit thereby dropping the haematocrit by 1%. The threshold 
haematocrit Is therefore reached with a lower intra-operative blood loss than if 
POD had not taken place. In addition the same patient not pre-donating could lose 
2500ml before requiring a transfusion, assuming a transfusion trigger of 
haematocrit 25%. Since losses of this magnitude are unusual, POD is not only an 
unnecessary expense for many patients but may actually adversely affect patients. 
However, for patients with large estimated blood losses, or low starting 
haematocrits, the use of POD can reduce exposure to allogeneic blood. 
Clinical Studies: 
In a recent meta-analysis Forgle et showed that patients who were 
randomised to receive autologous blood were less likely to receive allogeneic 
blood, but more likely than control patients to receive any transfusion, a fact also 
recognised by other authors® .^ There was a direct relationship between transfusion 
rate in the control group and benefit derived from POD, suggesting that other 
methods of decreasing blood transfusion, such as transfusion protocol and 
surgical technique, are important. 
A retrospective study looking at POD in prostatectomy showed that 3 unit POD 
decreased allogeneic exposure compared with controls. However, the study was 
retrospective, the controls were those who had been excluded from POD and 
totalled 10, compared with 384 trial patients'^. 
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Cost Effectiveness: 
Autologous blood donation is a more expensive process than the donation of 
allogeneic blood and up to half the units are discarded^^"®°. Furthermore, the 
addition of erythropoietin has also not been found to be cost effective®". Given the 
improved safety of allogeneic transfusions today, the increased protection afforded 
by donating autologous blood is limited and may not justify the Increased cost^ ®. 
Acute Normovoiaemic Haemodilution (ANH) 
Acute normovolaemic haemodilution is a technique in which whole blood Is 
removed from a patient, whilst circulating blood volume Is maintained with acellular 
fluid. It is performed shortly before a procedure that is anticipated to result in 
significant blood loss. By using this procedure prior to intra-operative blood loss, 
fresh autologous blood is made available for later transfusion. As a result of 
haemodilution, blood subsequently lost during surgery contains proportionally 
fewer red blood cells per millimetre, thus minimising intraoperative loss of 
autologous red cells. 
Venesected blood is collected in standard blood bank bags containing citrate 
anticoagulant. It is possible to utilise a tilt-rocker with an automatic cut off via 
volume sensors, thus freeing up staff®\ Blood can be stored at room temperature 
for up to 6-8 hours, or at 4 degrees centigrade for up to 24 hours®®'®\ 
Advantages: 
ANH has certain advantages: There Is minimal pre-operative preparation for both 
patient and staff, which makes ANH suitable for both emergency and elective 
procedures. Units are collected and stored at the bedside incurring no storage or 
testing costs, and minimising the chance of a clerical error leading to an incorrect 
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transfusion. All blood collected is returned to the patients thereby eliminating costly 
blood wastage. Since blood is available in theatre, patients can be "group and 
saved" allowing a lower cross match ratio. The blood is fresh, containing functional 
platelets and clotting factors and the lowered blood viscosity may have benefits In 
terms of oxygen delivery®"". 
Eligibility/Safety 
Any patient with a haemoglobin level of at least 11 g/dl and expected to lose more 
than 20% of their blood volume intra-operatively can be considered a candidate for 
ANH®®. These guidelines were echoed again in 1999®\ A 70 kg patient with a 
starting haematocrit of 45% can have 4 units removed before the haematocrit falls 
to 30%. Final haematocrits of 20% or 25% are safe because normovolaemia is 
maintained at all times by the infusion of acellular crystalloid or colloid. The 
sudden drop in haematocrit is accompanied by a decrease in the arterial oxygen 
content and is tolerated well by healthy adults due to the significant reserve of the 
oxygen delivery system: 1000 ml/min of oxygen are delivered to tissues, while only 
250ml/min are needed in the resting state. Anaesthesia further reduces oxygen 
consumption by 20% and cardiac output is also increased In response to the 
decrease In haematocrit. A shift in the oxygen dissociation curve does not occur 
during haemodilution. 
15% of a heterogeneous population of surgical patients have been found to be at 
risk for silent ischaemia when extensive preoperative monitoring was applied. 35% 
of these events occurred in patients not thought to be at high risk for Ischaemic 
heart disease on the basis of preoperative assessment®^. However, the rheological 
effects of ANH may be beneficial®''. Spahn et al®®, demonstrated that ANH to a 
haemoglobin of 8.8+/-0.3 g/dl was well tolerated in 20 patients older than 65 years. 
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The group went on to demonstrate that ANH was well tolerated to a haemoglobin 
of 9.9+/-0.2 g/dl In patients with coronary artery disease receiving B blockers®'*. 
Exclusions: 
Haemodilution is contraindicated in patients with severe myocardial disease of any 
cause®® (moderate to severe left ventricular impairment, unstable angina, severe 
aortic stenosis, critical left main stem disease) or cannot raise their cardiac output 
(previous infarction, calcium channel blockers or B blockers). However, as 
mentioned previously, Spahn et a P demonstrated that ANH was well tolerated to 
an haemoglobin of 9.9+/-0.2 g/dl in patients with coronary artery disease receiving 
Q> blockers. 
It is also contraindicated in those who do not have adequate reserve in their 
oxygen delivery system (restrictive or obstructive pulmonary disease) and may be 
contraindicated in patients unable to deal with large volume shifts (renal failure) or 
in patients with a coagulopathy that further dilution of clotting factors exacerbates. 
Furthermore, the effect of haemodilution on coagulation is still unknown. If 
haemodilution impairs coagulation, any beneficial effect may be negated by 
increased blood loss. 
Mathematical Model: 
For any given patient, the total red cell mass saved by ANH, and the extent to 
which the technique may reduce the need for allogeneic blood transfusion, 
depends upon three factors: 1) the Initial and target haematocrit; 2) the amount of 
blood venesected; and 3) the amount of surgical blood loss®®. Clinical studies of 
the efficacy of ANH have not examined the relative impact of these factors on red 
cell mass savings®®. Figure 3.1 illustrates the value of ANH. An adult with an 
estimated blood volume of 5 litres and an initial packed cell volume of 45% could 
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undergo surgical blood losses of up to 3000ml yet maintain a packed cell volume 
value that would remain >25% after operation. In this model, ANH from an initial 
packed cell volume of 45% would still allow up to 3500ml of surgical blood loss, 
and the packed cell volume could be maintained >28%. 
Feldman et al®® designed a model of ANH to understand the conditions where 
ANH is most likely to be beneficial to the patient and the degree of haemodilution 
required to achieve that benefit. In this model, patients were venesected to their 
minimum haematocrit prior to surgical blood loss. The venesected blood was then 
returned during surgical blood loss at a rate to maintain the minimum haematocrit. 
In their model, a unit of packed cells was taken as being 250ml with haematocrit of 
0.65. They showed that ANH can reduce the need for allogeneic transfusion, if 
used appropriately. However, the benefits were small (less than 2 units of 
allogeneic blood saved) unless a significant number of units are venesected (>7). 
This finding goes against the clinical studies in ANH which demonstrate 
considerable allogeneic transfusion savings. The authors conclude that well 
designed prospective studies are still required. 
The model designed by Brecher and Rosenfeld®'' took into account the continual 
decreasing haematocrit due to blood loss in an isovolaemic patient, largely by 
using differential equations. Once again, the venesected blood was returned to 
maintain the minimum haematocrit. In their model, a unit of packed cells was taken 
as being 350ml with haematocrit of 0.65. They found that for a typical patient with 
estimated blood volume 5000ml, pre-ANH haematocrit 0.40, minimum haematocrit 
at which transfusion was begun 0.25, over a range of blood losses (500-2500ml), 
and 1 to 5 units venesected, the savings never exceeded 0.6 units. In addition, 
taking into account the continual decreasing haematocrit, for a patient with 
haematocrit 0.45 who intra-operatively lost 1 litre of blood, the RBC volume would 
have been 408 ml. If the haematocrit had been reduced to 0.25, the RBC volume 
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lost would have been 227 ml, a saving of 181 ml. They concluded that published 
reports documenting substantial savings in allogeneic blood use with ANH were 
therefore surprising, and carefully controlled, prospective randomised trials were 
needed. 
Vamvakas et noted that based on the above model, an adult with an initial 
haematocrit of at least 45% could, without ANH, maintain a post-operative 
haematocrit of at least 25% and avoid an allogeneic transfusion, if there was an 
intra-operative blood loss of up to 3939ml. 
SingbartI et al®® commented that the mean volume of blood collected during ANH 
did not differ from the mean blood loss, concluding that the most cost effective 
method Is no ANH. They further commented that they knew of no PRCT 
comparing the efficacy of ANH with no ANH using the same transfusion trigger. 
16 17 18 19 20 21 22 23 24 25 26 27 28 
Minimum PCV (%) 
Figure 3.1: Maximal allowable blood loss in a patient with a blood volume of 
5000ml and an Initial packed cell volume value of 45% (solid line) or 40% (broken 
line), with and without ANH®^ 
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Efficacy Of ANH: 
Controlled Trials 
Wong et al^° looked at 145 patients, undergoing elective infra-renal aortic surgery, 
randomised to receive allogeneic transfusion or a combination of cell salvage and 
ANH. They demonstrated a significant reduction in the number of units transfused, 
but not the number of patients transfused. However, only a mean of 1.66 450ml 
units of blood were venesected for ANH, and since two variables were studied, it is 
impossible to know the relative effect of either one. 
In a three arm study, McGill et al^^ randomised patients undergoing cardiac 
surgery to cell salvage, ANH plus cell salvage and control. They demonstrated a 
significant reduction in the number of patients and units transfused in the cell 
salvage group compared with control, but no additional benefit with ANH. 
However, only lOml/kg blood was venesected during ANH. 
Boldt et al^^ looked at 60 patients undergoing retropubic prostatectomy divided into 
3 groups, ANH, controlled hypotension, and a control. They venesected a mean 
(SEM) 1278 (150) ml and replaced this with gelofusine at a ratio of 1:1. In the 
hypotensive group, they aimed to maintain MAP at 50mmHg using sodium 
nitroprusside. They found significantly fewer units of blood were transfused in the 
study groups, the hypotensive group having the least (21,14, and 28 respectively). 
The number of patients transfused in the 3 groups were 9, 5, and 12 respectively. 
However only a mean of 710ml extra fluid was administered to the ANH group 
compared with controls, implying that the ANH group were bled rather than 
haemodiluted. 
Goodnough et af^ proposed that ANH should replace POD. They argued that 
POD has the same effect as ANH: the haematocrit level reductions from POD (42 
to 36%) simply represent minimal chronic haemodilution, as shown in the section 
entitled "POD induced anaemia". These views were echoed by Rottman et al^ ® and 
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Monk et ar'*. The net result of this Is an increased likelihood of perisurgical 
transfusions and patients discharged with haematocrits lower than if they had not 
undergone poD®^ '®^ '®^ . The above Is only the case if the POD units are not all 
transfused, which assumes that POD transfusion carries the same risk as 
allogeneic transfusion. 
Two studies from the same author, appear to report the same accumulating cohort 
of patients® '^^ ®. All patients were haemodiluted to a haematocrit of 28% and the 
outcome compared with the additional effects of POD. Because 60% of POD units 
were wasted, there was a net loss of RBC In 80% of patients. There was a mean 
saving of 112+/-38ml of RBC attributed to ANH. Although they claimed that ANH 
can achieve an equivalent clinical outcome compared with POD, they compared 
their 21% transfusion rate in the ANH alone group with other studies reporting 
transfusion rates with POD. 
Herregods et al°® demonstrated no difference in ST segment depression in 
patients undergoing ANH to a haematocrit of 34% compared with controls during 
coronary artery bypass grafting. Although they demonstrated a significant 
decrease in allogeneic blood exposure with ANH, the control group had 
significantly greater blood loss. 
Olfsanger et al^^ found significantly greater number of units transfused in controls 
compared with patients haemodiluted to a target PCV of 28-30% (mean 1000ml 
collected) undergoing total knee replacement. However, only 30 patients were 
studied, randomised into 3 groups; 2 receiving ANH and 1 control. The control 
group had higher ASA grades and significantly greater postoperative blood 
losses^®. 
Oishi et aP^prospectively studied patients undergoing total hip replacement using 
ANH in combination with POD and cell salvage. Only 33 patients were studied and 
the strategies were too impractical and expensive. 
41 

Earlier studies were mostly flawed and the deficiencies have been well 
reviewed''""-''"* (inadequate numbers, differing populations of patients compared, 
wide variations in the volume of autologous blood withdrawn, no transfusion 
protocol, and most importantly, the use of historical controls). 
Meta-Analysis 
An Integration of the results of 5 randomised controlled trials by meta-analysis 
looking at the odds ratio of allogeneic transfusion in patients having ANH 
compared with POD revealed no significant difference®®'®^ They were selected 
randomised controlled trials. Two of the five were in press; one was foreign, one 
an abstract, and one from 1992. 
Bryson et al®^  demonstrated that trials without a transfusion protocol showed 
marked reductions in both the likelihood of exposure to allogeneic blood and the 
units transfused. In contrast, however, studies with a transfusion protocol failed to 
show statistical significant reductions in either. They concluded that larger trials 
with carefully defined indications for the transfusion of allogeneic blood are 
required to establish efficacy. 
Consensus Conferences 
The Royal College of Physicians of Edinburgh in 1995"*® ®* and 1998^ "*'^ ® noted that 
there was still no evidence that ANH was effective in reducing exposure to 
allogeneic RBC, and although serious hazards had not been reported, the 
physiological effects of the procedure remained uncertain. The panel concluded 
that randomised controlled trials were required before ANH could be widely 
recommended. This view was echoed by the British Committee for Standards in 
Haematology®®. 
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others 
Some critics have pointed to the modest conservation benefit of moderate ANH®®, 
and attribute any reduced allogeneic exposure to a more conservative transfusion 
practice. 
Faust et al®^  found that the additional crystalloid and colloid given during ANH can 
falsely dilute the intravascular haemoglobin level in the early postoperative period, 
making anaemia and allogeneic transfusion more likely. They also commented on 
the difficulty predicting which patients are likely to benefit in view of varied blood 
losses. 
Cost Effectiveness: 
ANH Is undoubtedly the cheapest fomi of autologous transfusion, however since 
the efficacy is unknown, it is impossible to comment on its cost effectiveness®®'^ ®. 
Monk et al®^  showed that transfusion costs were 73% higher for patients who had 
pre-donated 3 units of blood compared with those patients treated with ANH. 
ANH has been suggested as an inexpensive and effective means of reducing 
allogeneic blood exposure in a report of the American Society of 
Anaesthesiologists Task Force on blood component therapy'*'* 
Cell Salvage 
Blood salvage involves the collection of shed blood from the operative field or 
surgical drains and the return of that blood to the patient. Shed blood is suctioned, 
mixed with citrate anticoagulant, filtered, collected into a reservoir, washed with 
saline, concentrated and returned to the patient. 
Unprocessed salvaged blood differs from circulating blood because it has high 
levels of free haemoglobin and fibrin degradation products (FDP), free red cell 
stroma and procoagulant phospholipids, reduced and dysfuncfional platelets, 
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decreased levels of coagulation factors, and various amounts of surgical field 
debris. Transfusion of these products may result in nephrotoxicity, DIC, 
thrombocytopenia, coagulopathy and microemboli. Washing removes free 
haemoglobin, FDP, red cell stroma and procoagulant phospholipids, fat and fibrin 
emboli, cellular microaggregates, bone fragments, etc. 
Cell savage is contraindicated in the presence of potential contamination of the 
operative field by bacteria, malignant cells, amniotic or ascitic fluid®®, although 
recent published work suggests that the risk of dissemination of malignant disease 
is minimal®®. 
In one study, adverse reactions to transfusion of salvaged red cells occurred at a 
rate of 0.027% (5/18,506) units during a 6 year period®''. One death, due to air 
embolism during cell salvage, was reported to the New York State Department of 
Health between 1990 and 1995, out of 32,000 transfusions®^. 
Efficacy of cell salvage: 
The amount of RBC conserved depends on the rate of haemorrhage, the 
willingness of the surgeon to use an aspirator and not gauzes, the pressure of 
aspiration and the limitation of fomriation of bubbles during aspiration'*^. In addition, 
it has the potential to be used in emergency cases®®. 
For: 
The Royal College of Physicians of Edinburgh Consensus Conference concluded 
in 1995^ *® that an increasing body of evidence indicated that cell salvage could 
substantially reduce the need for allogeneic blood. The case had strengthened by 
1998'^ '*'^ °^ as evidence had accumulated that cell salvage was practical, safe, 
relatively inexpensive, and potentially even cost saving. A meta analysis of the 
effectiveness of cell salvage from ISPOT (International Study of Peri-operative 
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Transfusion) group showed that cell salvage in orthopaedic surgery decreased the 
proportion of patients requiring allogeneic transfusion^"®. In a three amn study, 
McGill et al^* demonstrated a significant reduction in the number of patients and 
units transfused in patients undergoing cardiac surgery. 
Against: 
However in 3 prospective randomised controlled trials, cell salvage did not result in 
fewer allogeneic transfusions^"'^°®. Bell et aP"'* showed a significant reduction in 
the number of units transfused from a median of 4 in controls to 3 in the cell 
salvage group, but not in the number of patients transfused in cardiac surgery. 
Wong et al^" also showed a significant reduction in the number of units transfused, 
but not the number of patients transfused in infra-renal aortic surgery, using a 
combination of cell salvage and ANH. Clagett et al*°® however, showed no benefit 
in cell salvage in elective Infra renal aortic surgery. Goodnough et al®''found that 
intra-operative cell salvage was not cost effective unless the blood loss exceeded 
1000ml. Most patients requiring transfusion clinically will generally require more 
blood than is available by salvage. Therefore, it may be of value, not because it 
reduces the requirements for transfusion, but because it provides blood that is less 
costly to obtain and is immediately available in the event of rapid blood loss. 
However, cost effectiveness has not been addressed in any large prospective 
controlled trial looking at outcomes^ "^. 
Post operative blood recovery (PBR) 
PBR is used most commonly in cardiovascular and joint replacement surgery. 
Studies looking at efficacy have reached disparate conclusions; at least 3 have 
shown lack of benefit whereas at least 2 have shown benefit®^ 
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Hypervolaemic Haemodilution 
Hypervolaemic haemodilution may provide the benefits of extreme haemodilution 
with a greater margin of safety^°®'''°®. 
Controlled Hypotension 
The concept of induced hypotension is to produce a reduction in peripheral 
vascular resistance and thus hydrostatic pressure while maintaining cardiac 
output^°^. Some haemodilution is likely to occur and may induce a state of 
hypervolaemia. The study by Boldt et al^^ showed that controlled hypotension with 
sodium nitroprusside resulted in the greatest reduction in number of units and 
patients transfused when compared with ANH or control in patients undergoing 
retropubic prostatectomy. 
Erythropoietin 
Recombinant human erythropoietin (epoetin alfa) is a glycoprotein that stimulates 
red blood cell production. Early data suggests that EPO alone decreases the 
exposure to allogeneic blood^''"'''''.^ and the benefit is greatest in anaemic patients. 
Recombinant human EPO and iron, administered to anaemic patients in a three 
centre ITU trial, decreased the number of transfusions^^®. Further evidence was 
gained from Mercurlali et al, who randomised 50 female patients undergoing total 
hip replacement into 3 groups; placebo and 2 different doses of EPO. They 
demonstrated that EPO decreased exposure to allogeneic blood in patients who 
were anaemic (haematocrit<39%). On this occasion supplemental iron was given 
intravenously as well as orally. EPO given with proper iron support can produce a 
mean increase of 1 g/dF. 
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EPO has been approved in the United States and Canada to increase the RBC 
mass of patients before elective s u r g e r y ^ E P O and ANH have been used in 
combination in patients undergoing radical prostatectomy^'''*. In that study, 
preoperative EPO was effective in minimising the perioperative anaemia 
associated with ANH and surgical blood loss, and the transfusion of allogeneic 
blood compared to patients undergoing either ANH alone or POD for blood 
conservation. Another study by the same group '^* demonstrated that EPO 
increased the haematocrit level in patients undergoing ANH and these levels 
remained significantly greater than a control group, undergoing ANH alone, at 
every measurement after baseline, including discharge. They also demonstrated a 
relationship between baseline haematocrit and transfusion rate. They further 
suggested that baseline haematocrit could be used to make an informed decision 
about EPO. This conclusion was also supported by Sowade et al^^^ in patients 
undergoing elective open heart surgery. 
The role of EPO In POD (pre-operative donation) is much more limited than initially 
expected. This is because no clinical benefit has been demonstrated in EPO 
treated donors, despite increased RBC production and collection in iron deficient 
donors. In a study comparing EPO with POD in 47 non-anaemic patients 
(haematocrit>39% at the time of first donation) undergoing orthopaedic 
procedures, EPO did not reduce exposure to allogeneic blood''®, but did allow a 
greater number of units to be donated. Price et al^ ®^ also showed that EPO can 
prevent anaemia and Increase the number of blood units collected during POD. 
The Royal College of Physicians of Edinburgh Consensus Conference concluded 
that the evidence of the value and safety of EPO in POD is unclear, and that any 
benefits from the use of EPO in this setting remain unproven^'*. 
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Side Effects: 
Most clinical experience using EPO Is in patients with chronic renal failure 
undergoing long-term administration. In this setting, well documented side effects 
include arterial hypertension, cerebral convulsions, and an influenza-like 
syndrome. Some studies have shown an Increase in thromboembolic events. The 
frequency and type of side effects from short term use are not well established. 
The results from an orthopaedic study have suggested the Increased possibility of 
deep vein thrombosis with EPO, especially if the baseline haemoglobin is greater 
than13g/dl^^®. 
Aprotonin 
Aprotonin has been shown in several systematic reviews of trials in cardiothoracic 
surgery to reduce the need for allogeneic blood and for re-operation because of 
continued bleeding^^ '^^ *®. However its efficacy has to be set against its high cost. 
Oxygen Carrying Solutions 
At the present time the two types of oxygen carrying fluids being developed are 
haemoglobin (Hb) solutions and perfluorochemical emulsions (PFC)^'"'''^. Oxygen 
carrying solutions have short effective lives (3-48 hours) and are plasma and 
platelet free. They include the cell free haemoglobin moieties derived from humans 
(10% diaspirin crbsslinked haemoglobin -DCLHb), xenobiotic products (bovine or 
pig based), recombinant human haemoglobin and synthetic perfluorocarbons. 
All of the Hb solutions appear to possess a vasoconstrictive effect which may be 
related to the binding of nitric oxide by the free haemoglobin solutions^-''^^. 
Concerns about endotoxin contamination and Immunogenicity also exist with 
several Hb solutions. 
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The only oxygen carrying solution approved for clinical use Is a PFC emulsion. Its 
use Is restricted to the perfusion of coronary arteries after percutaneous 
transluminal coronary angioplasty'"'''^^. Problems however Include short Intra­
vascular half life, low oxygen carrying capacity, poor shelf life and temperature 
instability. Until further studies are performed, these fluids remain experimental. 
Conclusion 
Meticulous surgical technique and the use of a transfusion protocol represent good 
practice. Pre-operative donation requires careful donor selection, venesection, 
adequate storage of blood and correct re-transfusion on a tightly defined time 
scale, often not practical in cancer surgery. Its efficacy remains questionable. Cell 
salvage and post operative blood recovery are currently not applicable in the 
presence of malignancy or when the bowel is open. Controlled hypotension and 
the use of EPO have had varying degrees of success, but have not been widely 
adopted. In the future, EPO may be used alongside other techniques, especially In 
the presence of anaemia. Aprotonin's efficacy has to be set against its high cost. 
Oxygen carrying solutions remain largely experimental at present. Acute 
normovolaemic haemodilution, however. Is a relatively inexpensive, simple, and 
safe technique which appears to be ideally suited to gastrointestinal surgery, 
however its efficacy is unproven. 
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Chapter 4: Current Blood Usage 
Aim 
The aim of this study was to ascertain the current departmental allogeneic 
transfusion requirements. 
Methods 
All patients undergoing colectomy surgery performed between 1997 and 1999 
were identified retrospectively from our colorectal cancer database. Subsequently 
the data collected was cross referenced with our haematology computers to 
Identify which patients had been transfused, the timing of transfusion 
(perioperative indicating on the day of surgery), and the number of units 
transfused. Pre-operative transfusions were excluded from the final analysis. 
Patients were grouped by ASA grade, as our target population for ANH were those 
of ASA 1 or 2. 
Results 
43% of the 470 identified patients were transfused a total of 532 units, 64 
perioperatively and 468 postoperatively (table 4.1). In the ASA 1 and 2 patients, 
41% of 333 were transfused a total of 357 units, 10 perioperatively and 347 
postoperatively (table 4.2). 
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PROCEDURE NO. 
PATIENTS 
NUMBER (%) 
TRANSFUSED 
Units 
Peri Post Total 
Right 
Fiemicolectomy 
107 43 (40) 22 84 106 
Extended Right 
Hemicolectomy 
39 18(46) 9 35 44 
Transverse 
Colectomy 
12 6(50) 2 8 10 
Left 
Hemicolectomy 
42 13(31) 3 23 26 
Sigmoid 
Colectomy 
38 8(21) 6 21 27 
Hartmann's 
Procedure 
22 15(68) 2 31 33 
Anterior 
Resection 
158 57 (36) 9 157 166 
AP 
Resection 
41 33(80) 8 87 95 
Subtotal 
Colectomy 
6 5(83) 3 9 12 
Panproctocolec 
tomy 
5 5(100) 0 13 13 
TOTAL 470 203 (43) 64 468 532 
Table 4.1: Transfusion rates for all ASA grades 
PROCEDURE NO. 
PATIENTS 
NUMBER (%) 
TRANSFUSED 
Units 
Peri Post Total 
Right 
Hemicolectomy 
78 28 (36) 9 13 22 
Extended Right 
Hemicolectomy 
24 10(42) 18 51 69 
Transverse 
Colectomy 
8 4(50) 0 6 6 
Left 
Hemicolectomy 
30 8(27) 1 16 17 
Sigmoid 
Colectomy 
23 5(22) 3 12 15 
Hartmann's 
Procedure 
11 8(73) 0 16 16 
Anterior 
Resection 
119 41 (34) 5 118 123 
AP 
Resection 
31 24 (77) 8 61 69 
Subtotal 
Colectomy 
4 3(75) 3 4 7 
Panproctocolec 
tomy 
5 5(100) 0 13 13 
TOTAL 333 136 (41) 47 310 357 
Table 4.2: Transfusion rates for ASA grades 1 and 2 
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Discussion 
The departmental transfusion rate Identified is similar to other published data 
(table 4.3). In view of the fact colorectal surgery is a high allogeneic blood usage 
field, any technique capable of reducing transfusion rates would therefore have a 
significant impact. 
Year Author Number Patients Transfused (%) 
1992 Jensen'" 197 104(53) 
1994 Houbiers'' 697 446 (64) 
1995 VignalP^" 161 86 (53) 
1996 Jensen'" 589 260(44) 
1998 Edna'^' 446 290 (65) 
2000 Mynster'''^ 740 452 (61) 
2002 Present Study 470 203 (43) 
TOTAL 3300 1841 (56) 
Table 4.3: Published transfusion rates In resections for colorectal cancer 
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Chapters: Patient Attitudes Towards An Allogeneic Transfusion 
Introduction 
Public opinion is a strong driving force. Although cost effectiveness is important in 
health science temris, a new technique is more likely to be adopted if there is 
positive public opinion. Likewise, if patient attitudes towards an allogeneic 
transfusion are largely negative, available alternatives are more likely to be 
favoured. 
Aims 
To assess patient's attitudes towards allogeneic transfusion and the alternative 
autologous techniques available. 
Methods 
Ethical approval was obtained from the Plymouth local research ethics committee. 
A questionnaire (figure 5.1) was administered to patients undergoing major 
gastrointestinal surgery, eligible for acute normovolaeniic haemodilution (group 1). 
Verbal information was subsequently given regarding the risks of an allogeneic 
transfusion (transfusion reaction, increased infectious complications, transmission 
of disease, alloimmunisation) and the technique of ANH. The questionnaire was 
re-administered by telephone at 30 days post-operatively and again at 3 months. 
The same questionnaire was administered to an age and sex matched control 
group of patients (group 2), having operations highly unlikely to require an 
allogeneic transfusion. The same Information regarding the risks of an allogeneic 
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transfusion and ANH was supplied and the questionnaire re-administered at 30 
days. 
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Figure 5.1: PATIENT PREFERENCE SURVEY 
In Derrlford Hospital we are looking at patients attitudes to blood transfusions. 
Please complete the following questionnaire. 
1. Are you:-
2. Age:-
Male 
18-25 
over 80 
Female 
26-40 41-60 61-80 
S.Occupation: 
4.Highest Educational Qualification: 
5. Have you had an operation before as an adult Yes 
which meant an overnight stay in hospital? 
In which year? 
6. Have you ever been a blood donor? Yes 
y.Have you ever had a blood transfusion before? Yes 
In which year? 
No 
No 
No 
8. Would you refuse a blood transfusion on religious/moral/ethical grounds? 
Yes 
No 
If yes go to question 10 
9. How willing would you be to accept a blood transfusion? (Tick one box) 
Very willing 
Somewhat willing 
Not sure 
Not very willing 
Very Unwilling 
lO.How safe do you think a blood transfusion is? (Tick one box) 
Very safe | ^ 
Somewhat safe _ 
Not sure 
Not very safe 
Very unsafe I 
11 .Are you aware that there are Medical techniques, which may allow you to avoid 
a blood transfusion from another person. Yes 
No 
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12.Are you aware of any of the following techniques? 
Pre op donation fZ 
Cell Saver _ 
Haemodilution 
Thank you for your time. 
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Results 
165 patients were recruited, group 1 n=127, group 2 n=38. Tliere were no 
significant differences between groups in baseline demographics/characteristics 
(table 5.1/5.2). 
Group 1 (%) Group 2 (%) 
Sex male 77 (61) 22 (58) 
female 50 (39) 16 (42) 
Age 18-25 4(3) 1(3) 
26-40 2(8) 3(8) 
41-60 37 (29) 17 (44) 
61-80 72 (57) 15(40) 
>80 4(3) 2(5) 
Table 5.1: Baseline demographics 
Group 1 Group 2 
n 127 38 
Previous surgery as adult % 84 72 
Previous blood donation % 37 24 
Previous transfusion % 19 18 
Aware autologous alternatives % 17 16 
Table 5.2: Baseline characteristics 
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The graphs below (figure 5.2) illustrate the percent of patients answering very or 
sonnewhat safe/willing in the 2 groups over the study period. 
study Group 
•Willing to Have 
Transfusion 
I Safe to Have 
Transfusion 
Day 0 Day 30 3 
Months 
Questionnaire Intervals 
p<0.001 Day 0 to Day 30, Day 0 to 3 months 
p<0.001 Day 30 to 3 months (willing) 
p=0.003 for Day 30 to 3 months (safe) 
Control Group 
• Willing to Have 
T rans fus ion 
• S a f e to Have 
T rans fus ion 
DayO Day 30 
Questionnaire 
Intervals 
p<0.001 day 0 to day 30 
Figure 5.2: Percent of patients answering very or somewhat safe / willing in the 2 
groups 
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Conclusion 
A majority of patients are willing to have an allogeneic transfusion (85%) and think 
it is safe (89%). Both education and undergoing major surgery coupled with a 
blood saving technique significantly effect attitudes, although the effect lessens 
with time. The lack of patient awareness of the risks of allogeneic transfusion has 
Implications in terms of uptake of alternatives available. 
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Chapter 6: A Prospective Randomised Controlled Trial Of 
Intravenous Fluid Replacement During Bowel Preparation For 
Surgery 
Introduction 
Two sachets of Picolax® (Ferring Pharmaceuticals Limited, Middlesex, UK) are 
administered to patients for bowel preparation prior to colonic surgery in our Unit. 
Sodium picosulphate is hydrolysed in the colon to reduce water and electrolyte 
absorption while the magnesium citrate acts as an osmotic laxative. It had been 
our impression that a large number of patients receiving bowel preparation were 
dehydrated when they came to surgery. One of the principles of acute 
nonnovolaemic haemodilution, is that the patient Is normovolaemic at all times. 
This prospective randomised controlled study was designed to assess the effects 
of administering intravenous fluid during bowel preparation. 
Methods 
Patients receiving bowel preparation for colonic procedures were recruited. Group 
1 was randomised by sealed envelope to receive no intravenous fluid while group 
2 received a calculated volume of intravenous normal saline during bowel 
preparation, which commenced at the same time as taking Picolax (i.v. infusion 
rate per hr = 4mls/kg for the first 10kg + 2mls/kg for the second lOkgs + 1 ml/kg for 
each subsequent kg). Both groups received two sachets of Picolax® six hours 
apart starting eighteen hours before their procedure and were encouraged to drink 
unlimited clear fluids until six hours before that time. The study received approval 
from the Plymouth local research ethics committee and patients were required to 
give informed consent for their Inclusion. 
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Physiological (weight, pulse, supine and erect blood pressure) haematological 
(haemoglobin, haematocrit) and biochemical (sodium, potassium, urea, creatinine, 
urine osmolality) variables were measured immediately before administering bowel 
preparation and repeated one hour prior to their procedure or immediately before 
premedication. A sample size of twenty in each group was estimated based on 
finding a difference in weight between groups of 0.5kg with a standard deviation of 
0.55^^ ®, power of 80% and significance level of 0.05. Weight was measured to the 
nearest half kg using a single Seca (Hamburg, Germany) analogue scale, which 
was checked annually by the Bristol Scales Company (Bristol, UK). Care was 
taken to ensure the same clothing was worn at both weighings. Blood pressure 
and heart rate were measured with the Dinamap Compact TS (Johnson & 
Johnson Medical Inc, Tampa, Florida, USA). Supine readings were taken after 
lying undisturbed for 30 minutes. Subsequent erect readings were taken two 
minutes after sitting or standing. In addition, total fluid intake and output, American 
Society of Anaesthetists (ASA) grade^ '^*, and weight of faeces were recorded. 
Fluid intake included oral and intravenous fluids. 
Data was assessed for normality using the Shapiro Wilk test and subsequently 
analysed within groups and between groups using paired and unpaired t-tests as 
appropriate. A p<0.05 was taken as being significant. 
Results 
Forty-one patients were recruited with a median age 69 years (range 29-86), 
group 1 n=22, group 2 n=19. There were twenty six males and fifteen females. 
There was no difference between groups in baseline variables, age, sex, ASA 
grade, or diagnosis prior to bowel preparation and no evidence of non-normality in 
any of the variables studied (tables 6.1-6.3). On completion (table 6.2 and 6.3), 
there was a significant difference between groups in mean weight loss (p=0.01), 
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postural change in systolic pressure (p=0.015) and serum creatinine (p=0.008). In 
addition there was a significant difference within group 1 in weight loss (p<0.001), 
fall in erect systolic pressure (p=0.011) (graph 1), fall in erect diastolic pressure 
(p=0.023), and fall in supine diastolic pressure (p=0.005). Serum potassium 
concentration decreased significantly in groups 1 and 2, p=0.019 and p<0.001 
respectively and supine pulse rate increased significantly In both groups p=0.046 
and p=0.047 respectively. The mean difference in fluid input in the two groups was 
2078ml. The mean urine output in group 1 was 982ml and group 2 1808ml 
(p=0.004) but the faeces weight was not significantly different (p=0.93) between 
groups (table 6.4). 
Group 1 (22) Group 2 (19) 
Sex Male Female Male Female 
13 9 13 6 
Age 69 (29-86) 69 (34-85) 
ASA 2 (1-3) 2 (1-2) 
Table 8.1: Patient demographics (median and range) 
Variable Group Initial Change P 
Weight (kg) 1 77.8 (3.9) -1.6 (0.2) <0.001 
2 75.1 (3.1) -0.5 (0.3) 0.12 
P 0.72 0.011 
Creatinine 
(pmol/L) 
1 96.5 (6.0) +1.8 (1.5) 0.24 
2 91.6(4.8) -3.8 (1.3) 0.009 
P 0.53 0.008 
Table 6.2: Mean (SEM) change in variable before and after picolax 
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Variable Group Initial Final P 
Postural Pressure 
Drop* 
(mmHg) 
1 -1.6 (3.4) 7.2 (4.0) 0.08 
2 -2.9 (2.9) -5.7 (3.1) 0.47 
Erect Systolic Pressure 
(mmHg) 
1 145 (3.8) 132(6.5) 0.011 
2 142 (4.5) 137(5.2) 0.40 
Erect Diastolic 
Pressure 
(mmHg) 
1 84 (2.5) 77(2.8) 0.023 
2 84 (2.4) 80 (3.5) 0.30 
Supine Diastolic 
pressure 
(mmHg) 
1 81 (1.7) 75 (2.1) 0.005 
2 79 (2.5) 79 (2.0) 0.95 
Potassium 
(mmol/L) 
1 4.4(0.10) 4.1 (0.10) 0.019 
2 4.4 (0.07) 4.1 (0.07) <0.001 
Supine Pulse 
(bpm) 
1 77 (2.8) 82 (2.5) 0.046 
2 76 (2.6) 82 (3.4) 0.047 
*Significant diiference between groups after picolax p=0.015 
Table 6.3: Mean (SEM) variable before and after picolax 
Total Fluids in (ml) 
Urine 
Output (ml) 
Faeces Weight 
(g) 
Group 1 1669 (254) 982 (129) 1203 (182) 
Group 2 3747 (359)* 1808(253) 1183 (139) 
P <0.001 (1269-2886) 0.004 (275-1377) 0.93 
Total fluids includes oral and intravenous 
*Mean IV input 2 litres; mean oral Intake 1.7 litres 
Table 6.4: Mean (SEM) fluid input, urine / faeces output 
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Discussion 
Picolax bowel preparation has previously been shown to cause a significantly 
greater weight loss and increased haemoglobin concentration compared with a 
group of matched patients undergoing body surface surgery^^®. Patients of ASA 
grade 3 were noted to feel faint on standing, after bowel preparation. Kutt et al*^ ® 
also demonstrated an Increase in haemoglobin concentration prior to barium 
enema examination. In addition there was a correlation between patients with a 
raised haerrioglobln and those experiencing headache. In a retrospective study, 
Lee et al^ ®^ looked at peri and post-operative fluid requirements in patients 
undergoing in-patient versus outpatient bowel preparation. The In-patient group 
were given IV fluids overnight whereas the outpatient group commenced IV fluids 
one to two hours prior to surgery. Although there was a shorter length of stay in 
the outpatient group, they also had Increased peri and post-operative fluid 
requirements. 
Lawrance et al^^^ in a prospective randomised study looked at five different oral 
fluid regimens in 197 patients and found no difference in any of the groups with 
regard to adverse events. Hill et aP^® demonstrated that patients with cellular 
potassium depletion were at risk of hypokalaemia after bowel preparation with 
sodium phosphate. 
The current study confirms the dehydrating effect of Picolax® bowel preparation 
as measured by the decrease in weight, erect systolic, erect diastolic and supine 
diastolic pressures in group 1, and the significant difference in postural pressure 
change between groups. None of these variables changed significantly in group 2, 
signifying that the dehydrating effect was negated with the administration of 
intravenous saline. Interestingly, although both groups were encouraged to drink 
unlimited clear fluids during preparation, their oral intake was not significantly 
different (table 6.4). In both groups the serum potassium concentration decreased 
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significantly. The supine pulse rate increased significantly in both groups implying 
a cause other than hypovolaemia. 
In conclusion, Picolax® bowel preparation has significant clinical effects, which 
may be particularly detrimental in elderly or cardiovascularly compromised 
patients. Furthermore, the use of an epidural results In vascular dilatation 
amplifying any pre-existing hypovolaemia. It is therefore extremely important to 
correct these dehydrating effects prior to any venesection for haemodilution. This 
can be achieved by administering a simultaneous volume of Intravenous fluid 
(mean 2 litres in this study). Consideration should also be given to potassium 
replacement. 
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Chapter 7: Acute Normovolaemic Haemodilution In Colorectal 
Surgery - A Pilot Study 
Introduction 
The aim of this pilot study was to assess whether ANH reduced exposure to 
allogeneic blood, affected clinical outcome and hospital stay, and is feasible in 
colorectal surgery. 
Methods 
The study received approval from the Plymouth local research ethics committee. 
All patients admitted for major colorectal surgery were screened for haemodilution 
eligibility (Hb>11g/dl, ASA 1 or 11) and infonned consent obtained. 
Standard pre-operative preparation included FBC, U&E, cross match according to 
procedure, ECG and CXR. Picolax® (Ferring Pharmaceuticals Ltd, Middlesex, UK) 
bowel preparation, if required, was administered the day before surgery. The 
resulting dehydration was minimised by administering two litres of N/Sallne with 
20mmol potassium intravenously over 12 hours, commencing in the evening, prior 
to surgery^^^. 
Haemodilution commenced in the anaesthetic room and continued in the operating 
theatre If needed. The volume of blood to be withdrawn (maximum 3 units), whilst 
maintaining the haemoglobin above 8g/dl, was calculated using a formula 
described by Gross^®° (figure 7.1). A 14 gauge cannula was sited in either the 
external jugular vein or a large forearm vein. Extension tubing with a three way tap 
and rubber bung was connected which allowed access away from the surgical 
drapes. Standard blood bags containing anticoagulant citrate-phosphate-dextrose 
(CPD) were used to passively collect the blood. The bags were placed on scales 
on the floor and Oscillated by hand during venesection to allow adequate mixing of 
66 
' ' i l l . . . t ' ~t ' ' - : 
anticoagulant. Once filled, the blood bag tubing was clamped, the bag labelled and 
stored with the patient at room temperature in the operating theatre. 
Wanned cell free fluid was administered via a second cannula during blood 
withdrawal to maintain normovolaemia. The first litre of blood withdrawn was 
replaced with 1 litre of gelofusine. Subsequent blood withdrawal was replaced with 
Hartmann's at a ratio of 3 or 4:1. A Hemocue B-Haemoglobin photometer 
(Hemocue Ltd, Sheffield, UK) undergoing regular quality control, checks was 
present in theatre to allow near patient haemoglobin testing. 
The patient was monitored during the operation using standard equipment for the 
operation concerned. Minimum monitoring included continuous ECG, pulse rate 
and oxygen saturation. Radial artery catheters and central venous lines were used 
at the anaesthetist's discretion. At the end of the operation, all the autologous 
blood was re-transfused. If, at the anaesthetist's discretion, a patient required a 
transfusion prior to the completion of surgery, autologous blood was used prior to 
any allogeneic. 
Haemoglobin, haematocrit, and clotting (APTT, INR) were measured before and 
after haemodilution, hourly through the procedure, and before and after re-
transfusion. 
Patients in the haemodilution group undenwent standard postoperative care 
including adherence to a transfusion protocol (figure 7.1). Primary outcome 
measures included the number of patients transfused and the number of units 
transfused. Secondary outcome measures Included time taken to venesect, 
complications and length of stay. 
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V = E B V * ( H O - H F ) / H A V 
Ho = initial liaematocrit or Hb concentration 
Hp = target haematocrit or Hb concentration 
HAV = average of haematocrits or Hb concentration 
EBV = estimated blood volume (70 ml/kg man, 65 ml/Kg woman) 
Figure 7.1: Formula for Volume of Blood Withdrawn 
Haemoglobin >10g/dL No Transfusion 
Haemoglobin 8 - 1 0 g/dL Transfuse if: Abnomnal ECG or, 
Ischaemic Heart Disease or. 
Obstructive Lung Disease or. 
Consultant's Discretion or. 
Unable to absorb oral iron 
Haemoglobin < 8g/dL Transfuse 
Figure 7.2: Transfusion Protocol 
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Results 
123 of 317 (39%) ASA 1 and 2 patients operated on between 1997 and 1999, and 
matched for type of operation, were transfused a total of 328 allogeneic units 
(median 2, range 1-7) (table 7.1). 
Between October and December 1999, 26 of 55 (47%) patients screened for 
eligibility were recruited for ANH. 18 male and 8 female patients with a median age 
of 58 years (range 34-75) undenvent operations (table 7.1). Five patients were 
venesected 3 units, twenty 2 units, and one had one unit. Four of the twenty six 
patients (15%) were transfused a total of thirteen allogeneic units (median 3, range 
2-5). The reduction in the number of patients transfused from 123/317 (39%) to 
4/26 (15%) was statistically significant p=0.017 (Chi square). Haemodilution 
increased anaesthetic time by a median of 19 minutes (range 9-40). There were 
no post operative complications in the ANH group and no significant alterations in 
clotting during haemodilution. The median length of stay was 9 days (range 6-13). 
Procedure Non-haemodiluted Haemodiluted 
No. 
Patients 
No.T* 
(%) 
Total 
Units 
No. 
Patients 
No.T* 
(%) 
Total 
Units 
Right/Ext Right 
Hemicolectomy 
110 42 (38) 97 1 0 0 
Left 
Hemicolectomy 
53 13(25) 32 6 0 0 
Anterior 
Resection 
119 41 (34) 123 13 3(23) 11 
AP 
Resection 
31 24(77) 69 4 1(25) 2 
Subtotal 
Colectomy 
4 3(75) 7 2 0 0 
TOTAL 317 123 (39) 328 26 4(15) 13 
* Number patients transfused (%) 
Table 7.1: Allogeneic blood usage in non-haemodiluted and haemodiluted patients 
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Discussion 
47% of patients screened were eligible for ANH. The majority were excluded 
because of anaemia and co-morbid disease. However, in this pilot study of 
selected patients ANH is a feasible and effective method of reducing allogeneic 
blood exposure in major colorectal surgery. Although the control group was 
matched for ASA grade and operation, it remains historical. A prospective 
randomised controlled trial is now urgently required. 
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Chapter 8: Acute Normovolaemic Haemodilution In Gastro­
intestinal Surgery-A Prospective Randomised Controlled Trial 
Aim 
The aim of this study was to define the role of acute normovolaemic haemodilution 
in gastrointestinal surgery In terms of its potential as a blood saving technique, and 
the effects on clinical outcomes and hospital stay. 
Methods 
The study received approval from the Plymouth local research ethics committee. 
All patients under the care of the twelve participating surgeons admitted for major 
colorectal, gastric or pancreatic surgery were screened for eligibility. Absolute 
exclusion criteria included Hb<11g/dl, age<18 years, and blood or blood products 
in the preceding four weeks. Exclusion criteria at the Investigators' and/or 
anaesthetists' discretion included abnonnal ECG, ischaemic heart disease, 
obstructive lung disease, renal disease, hypertension, abnormal liver function and 
coagulation abnomnality. Informed consent was obtained and the patient remained 
blinded to treatment allocation throughout the study period. Refer to chapter 7, 
page 66 for further method details. 
Oropharyngeal temperature was measured at knife to skin and again at the end of 
the operation. Blood loss was estimated by swab weight, suction volumes and 
surgeon / anaesthetists estimates. Patients undenwent standard postoperative 
care including adherence to a standard transfusion protocol''"® (figure 8.1). Urine 
output was measured hourly for at least 24 hours. Oliguria was defined as urine 
output < 30ml/hr. Full blood count and urea and electrolytes were measured at 24 
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and 48 hours with the former measured again at discharge and 30 days. Patients 
were followed up at 30 days, 3 months and 6 months by telephone. 
Primary outcome measures included the number of patients transfused and the 
number of units transfused. Secondary outcome measures included time taken to 
venesect, complications and length of stay; 
A sample size of n=80 was calculated based on reducing allogeneic blood 
exposure from 41% (transfusion rate for ASA 1 and 11 patients undergoing 
colectomy surgery from 1997 to 1999 inclusive) to half, 20.5%, with a two tailed 
power of 80% and significance level of 0.05. Randomisation was by medium sized 
variable blocks and obtained by telephone to a distant centre. 
Continuous data was analysed using the Student t test or Mann Whitney U 
depending on the distribution of the data. Proportional data was analysed using 
the chi-squared and Fishers exact test. All analysis was perfonned on an intention 
to treat basis with a p<0.05 taken as being significant. Logistic regression was 
used to identify factors associated with the need for a transfusion. The model was 
built in stages and factors significant at the 10% level were retained. Interactions 
among variables were examined. 
Pyrexia was defined as a temperature of greater than 37.5 C over a period of 48 
hours on two or more occasions, with negative urine, wound, sputum and blood 
cultures and requiring antibiotics. Wound infection was defined as an accumulation 
of pus with spontaneous discharge or requiring surgical drainage and was graded 
as minor or major. Cellulitis with associated pyrexia and raised white cell count 
was regarded as minor. Deep infection was defined as pelvic or intraperitoneal 
infection as diagnosed by imaging or laparotomy. Septicaemia was defined as 
positive blood cultures in association with swinging high pyrexia. Chest infection 
was defined as productive cough, pyrexia and abnormal CXR. Urinary tract 
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infection was defined as a positive culture > 1000 organisms / ml With associated 
pyrexia. 
Haemoglobin >10g/dL No Transfusion 
Haemoglobin 8 - 1 0 g/dL Transfuse if: Abnonnal ECG or, 
Ischaemic Heart Disease or. 
Obstructive Lung Disease or, 
Consultant's Discretion or. 
Unable to absorb oral iron 
Haemoglobin < 8g/dL Transfuse 
Figure 8.1: Transfusion Protocol 
Results 
During an eighteen month period, 316 consecutive patients were screened of 
which 160 (51%) were eligible, ANH n=78, no ANH n =82. The median age was 62 
years (range 23-90) and 84 were male, 76 female. There was no difference 
between groups In age, sex, weight, starting haemoglobin, type of operation, 
duration of operation and blood loss. There was a statistically significant difference 
between the groups in both pre-operative and post-operative temperature (p<0.01) 
(table 8.1), however the difference in median temperatures was 0.1 °C and 0.3° C 
respectively. 
There was no significant difference between groups in the number of patients 
receiving allogeneic blood 23/78 (29%) versus 25/82 (30%), or the total number of 
allogeneic units transfused (92 versus 93). The number of patients transfused 
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perioperatively or In recovery in the two groups were 15/78 and 20/82. Post­
operatively, days 1-3, 9/78 and 8/82 were transfused (table 8.2). The type of 
operation perfonned and transfusion rates are shown in table 8.3. 
The most significant factors affecting transfusion were blood loss, starting 
haemoglobin and age (table 8.4, figure 8.2-8.4). In the ANH group, the allogeneic 
transfusion rate was lower in those patients with an estimated blood loss of 
>750ml (16/42 versus 24/46, p=0.185), but higher in those patients with an 
estimated blood loss of <750ml (7/36 versus 1/36, p=0.055) (table 8.2). A test for 
interaction as to whether there was a difference in effect between high and low 
blood loss groups was marginally significant (Chi square p-0.007). 
When compared with ASA matched historical controls, the introduction of a 
transfusion protocol reduced the transfusion rate in the colorectal patients from 
136/333 (41%) to 38/138 (28%), p=0.006. 
There was no significant difference in the transfusion triggers in each group (table 
8.5). However, In 6 patients, 3 in each group, the transfusion protocol was violated 
and transfusion occurred postoperatively with a haemoglobin > 8d/l. 
There was no significant difference in haemoglobin levels between groups 
throughout the study period (table 8.6). in addition, there was no significant 
difference in pre-operative and day 2 calculated (figure 8.5) RBC loss (ANH 614ml 
SD 427, no ANH 616ml SD 451). The median lowest Intra-operative pre 
autologous transfusion haemoglobin in patient's haemodiluted was 7.7 g/dl (4.8-
11). 
Venesection lasted a median of 30 minutes (10-70), and significantly increased 
anaesthetic time, median 55 minutes (range 15-90) versus 40 minutes (range 17-
80) (p<0.001). Significantly fewer patients in the ANH group experienced oliguria 
in the immediate post-operative period 37/78 (47%) versus 55/82 (67%) (p=0.012). 
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There was no significant difference in complication rate in the 2 groups (table 8.7), 
however the complication rate was significantly greater in patients- who received 
allogeneic blood compared with those who did not, 16/48 (33%) versus 20/112 
(18%) (p=0.03). 
There was no significant difference in the number of postoperative days stay in the 
2 groups, median 8 (5-110) versus 10 (5-92), ANH and no ANH respectively. 
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ANH (78) Control (82) 
Sex Male Female Male Female 
43 35 41 41 
Age (years) 62 (23-85) 62.5 (24-90) 
Weight (kg) 74 (14) 73 (15) 
Starting Hb (g/dl) 13.5(1.2) L 13.5(1.3}^  
Duration operation (hr:min) 1:53 (0:45-5:20) 1:55 (0:15-5:08) 
Blood Loss (ml) 750-1000 (100-4500) 750-1000 (100-4368) 
*Temp start ("C) 35.7 (34.7-36.8) 35.8 (35.0-36.7) 
*Temp end (°C) 35.5 (33.9-37.1) 35.8 (34.5-36.9) 
**Fluid Input (ml) 4500(2000-11000) 3500 (1100-9000) 
**GA Time (min) 55 (15-90) 40 (17-80) 
Venesection Volume (ml) 1350 (0-1454) 
Results in median (range) except weight and starting H b mean (sd) 
*p<0.01 
**p<0.001 
Table 8.1: Patient demographics and baseline measures 
All Blood loss < 750ml Blood loss > 750 
All DayO Day 
1-3 
All Day 
0 
Day 
1-3 
All DayO Day 
1-3 
A 
N 
H 
Patients 
% 
23/78 
29 
15/78 
19 
9/78 
12 
7/36 
19 
5/36 
14 
1/36 
3 
16/42 
38 
10/42 
24 
8/42 
19 
Units 92 52 26 23 18 3 69 34 23 
Median 
(range) 
3 
(2-14) 
3 
(2-8) 
3 
(2-4L 
2 
J2-8) 
2 
(2-8) 
3 3 
(2-14) 
3.5 
(2-6) 
3 
(2^) 
8/46 
17 
C 
0 
N 
T 
R 
0 
L 
Patients 
% 
25/82 
30 
20/82 
24 
8/82 
10 
1/36 
3 
1/36 
3 
0 24/46 
52 
19/46 
41 
Units 93 56 22 1 1 0 92 55 22 
Median 
(range) 
3 
(1-16) 
2 
(1-5) 
3 
(2-4) 
1 1 0 3 
(2-16) 
2 
(2-5) 
3 
(2-4) 
Table 8.2: Transfusion rates by timing of transfusion and blood loss 
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ANH (78) Control (82) 
Number Transfused 
(%) 
Number Transfused 
(%) 
Right hemi­
colectomy 
8 1 (12.5) 8 0(0) 
Left hemi-colectomy 23 1 (4) 22 2(9) 
Rectum 33 16 (48) 39 16 (41) 
Subtotal 4 1(25) 2 1(50) 
Panproctocolectortiy 0 0(0) 1 1 (100) 
Whipples 3 , 2(67) 5 4(80) 
Gastrectomy 3 0(0) 2 0(0) 
Other 4 2(50) 3 1(33) 
Others: 2 gastroenterostomies, 2 division adhesions, 1 biopsy pancreas, 1 
strictureplasty, 1 excision sarcoma (left abdomen) 
Table 8.3: Type of operation and transfusion rate: 
Variable N Odds Ratio 95% Confidence 
Interval 
Haemoglobin / Ig/dl increase 160 0.43 0.28-0.65 
Blood loss <500 45 1.00 -
501-1000 39 4.17 0.91-18.91 
1001-1500 43 13.37 3.22-55.54 
>1500 33 54.76 11.54-259.82 
Age / year increase 160 1.03 1.00-1.07 
Table 8.4: Multivariate logistic regression model for transfusion 
1 -
d -
'—I • r 1 1 1 1 r-
11 12 13 14 IS 16 17 
preoperative tiaemoglobin 
Bloodless iSOO 501-1000 1001-1500 >1500 
Figure 8.2: Graph showing the estimated relationship between pre-operative 
haemoglobin and the probability of transfusion by blood loss for a patient aged 82 
(median) 
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preoperative haemoglobin 
Blood loss £ 5 0 0 501-1000 1001-1500 >1500 
Figure 8.3: Graph showing the estimated relationship between pre-operative 
haemoglobin and the probability of transfusion by blood loss for a patient aged 53 
(lower quartile of age distribution) 
0 -
I—I 1 1 , , , p-
11 12 13 14 15 16 17 
preoperative haemoglobin 
Bloodless £ 5 0 0 501-1000 1001-1500 >1500 
Figure 8.4: Graph showing the estimated relationship between pre-operative 
haemoglobin and the probability of transfusion by blood loss for a patient aged 70 
(upper quartile of age distribution) 
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Hb Trigger Day 0 (g/dl) Hb Trigger Day 1-3 (g/dl) 
ANH 7.1 (4-8.6) n=14/15 7.4 (5.2-12.2) n=9/9* 
Control 7.5 (4.7-8.0) n=9/20 7.7 (7.2-9.8) n=8/8** 
*3 out of 9 patients transfused with trigger > 8 (9.8, 9.9,12.2) 
**3 out of 8 patients transfused with trigger > 8 (8.3, 8.5, 9.8) 
Table 8.5: Allogeneic transfusion triggers 
ANH n Control n 
Hb Day 1 (g/dl) 10.5(6.0-15.4) 74 10.8 (7.2-15.0) 76 
Hb Day 2 (g/dl) 10.8 (6.9-14.9) 67 10.4 (7.5-15.0) 69 
Hb Discharge (g/dl) 11.8 (8.4-14.7) 75 11.7(8.7-14.9) 73 
Hb Day 30 (g/dl) 12.4 (9.2-16.0) 64 12.3 (7.5-14.8) 65 
Table 8.6: Haemoglobin variation during study period 
RBC loss = (EBV * (Hcto-Hct2)) + (250 * number units transfused by day 2) 
EBV = estimated blood volume (70 ml/kg man, 65 ml/Kg woman) 
Figure 8.5: RBC Loss'*^ ®^ 
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(\NH (78) Control (82) Transfused 
Total Trans No 
Trans 
Total Trans No 
Trans 
Yes* 
(48) 
No* 
(112) 
Pyrexia 0 0 0 3 1 2 1 2 
UTI Dis 5 5 0 4 2 2 7 2 
30 3 0 3 3 0 3 0 6 
RTI Dis 1 1 0 1 1 0 2 0 
30 1 0 1 0 0 0 0 1 
Wound 
Infection 
Dis 1 1 0 5 2 3 3 3 
30 2 2 0 1 0 1 2 1 
Deep 
Infection 
1 1 0 0 0 0 1 0 
Septicaemia 1 1 0 1 1 0 2 0 
DVT 2 1 1 2 1 1 2 2 
PE 0 0 0 2 1 2 0 2 
Leak 0 0 0 3 2 1 2 1 
Death 2 2 0 1 0 1 2 1 
Total 19 14 5 26 10 16 24 21 
Dis: discharge 
30: day 30 
Trans: allogeneic transfusion 
Complications by transfusion: 
1) Number complications 
Transfused (24/48) 
Not transfused (21/112) 
p=0.049 (Chi square) 
2) Number of patients with complications: 
Transfused 12*1,1*2,2*3,1*4 = 16 patients/48 
Not Transfused 19*1,1*2 = 20 patients/112 
p=0.032 (Chi square) 
Complications by Group: 
1) Number of complications 
ANH 19/78 
No ANH 26/82 
2) Number of patients with complications: 
ANH: 11*1,2*2,1*4 = 14 patients/78 
Control 20*1,2*3 = 22 patients/82 
p=0.179 
Table 8.7: Complications by group and by presence of transfusion 
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Discussion 
51% of 316 patients screened were eligible for ANH. A majority were excluded 
because of co-existing medical disease or a pre-operative haemoglobin <1 Ig/dl 
(44). Two patients were excluded because of HIV. A further 64 were eligible, but 
excluded because of lack of trial staff (48), refusal to enter the study (9), and no 
access/time to randomise (7). Therefore true eligibility, if the technique were to be 
adopted, would be 59% (224/380). 
The number of patients receiving allogeneic blood and number of units transfused 
in the 2 groups were virtually identical (29% and 30%, 92 and 93 units). It is 
interesting to observe the transfusion rates In the 2 groups, broken down by blood 
loss (table 8.2), as mathematical modelling has shown that It is procedures with 
significant blood loss that are likely to benefit. In those patients with a blood loss of 
> 750ml, fewer were transfused In the ANH group (16/42 compared with 24/46), 
compared to greater number of patients transfused in the ANH group when the 
blood loss < 750ml (7/36 compared with 1/36). The dilutional effect can result in 
"falsely" diluted haemoglobin levels thereby triggering transfusion when it is not 
required. This point has been realised by other authors® .^ If the ANH group were 
significantly over transfused when the blood loss was < 750ml, one would expect 
the haemoglobin levels postoperatively to have reflected this. However, the 
haemoglobin levels in each group on days 1, 2, discharge and 30 (table 8.6) were 
also virtually identical as was the calculated RBC loss, it remains possible that in 
high blood loss groups, haemodilution does marginally reduce allogeneic 
transfusion, and our subgroup is underpowered to show this. 
Logistic regression identified 3 factors which affect transfusion; starting 
haemoglobin, blood loss and age, which concurs with previous studies^''. 29% of 
the 154 patients excluded were so because of a starting haemoglobin of <11g/dl. 
Looking at the entire study population (380 patients), 29% had a starting 
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haemoglobin <12g/dl and 47% <13g/dl. These figures imply that pre-operative 
boosting of haemoglobin level may be of use in decreasing allogeneic transfusion. 
The introduction of a transfusion protocol significantly reduced our unit's 
transfusion rate from 41% to 28%, illustrating that the presence of a transfusion 
protocol will reduce transfusion rates, thereby explaining the large allogeneic 
savings seen In studies with historical controls. 
The median volume of blood venesected was 1350ml (0-1454). 11 patients had 
less than 800ml venesected; 5 had no blood venesected, 4 due to failed IV access 
and the other due to consultants decision in theatre (listed for major operation, 
minor performed). In total 56/78 (72%) patients had the desired > 1000ml 
venesection. The main reasons for failure Included poor venous access resulting 
in low flow or clot formation in the tubing, and anaesthetist discretion preventing 
further venesection. Excluding those patients with < 1000ml venesection from 
analysis, again resulted in no significant difference in transfusion rates 14/56 
(25%) versus 25/82 (30%). 
Haemodilution increased anaesthetic time by a median of 15 minutes, despite 
haemodiluting during insertion of epidurals, urinary catheters and draping the 
patient. This delay would have cost implications, if the technique were to be 
adopted. 
Although there was no significant difference in complication rate between groups, 
there was a significantly Increased complication rate in those patients who 
received allogeneic blood. This occurred despite the use of leucocyte depleted 
allogeneic blood. It is still unclear whether it is the events necessitating 
transfusion, rather than transfusion itself exerting an effect. 
The Haemocue may have had an effect on transfusion rate, as demonstrated in 
other studies^®''. 
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In conclusion, In this, the largest study performed in the past 25 years, ANH did 
not affect allogeneic transfusion rate, complication rate or length of stay in major 
gastro-intestinal surgery. Pre-operative haemoglobin, blood loss and transfusion. 
protocol are the key factors influencing allogeneic transfusion. 
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Chapter 9: The Effects of Surgery And Acute Normovolaemic 
Haemodilution On Coagulation As Measured By The 
Thromboelastogram 
Introduction 
Replacement of a proportion of blood volume with crystalloid or colloid may have 
an effect on haemostasis. However, what this effect is and the degree of 
haemodilution at which it occurs is unknown. Furthermore, surgery in conjunction 
with blood loss, may also affect coagulation, by activation of coagulation and 
fibrinolysis with concomitant consumption of coagulation factors. 
There are a number of methods to quantify the hypothesised effect. The most 
important effect on haemostasis (the one which will affect the adoption of ANH as 
a technique) Is clinical. If haemostasis is suppressed then total blood loss (at 
operation and ongoing) would be increased, blood requirement increased and 
relative Hb may be lower. If ANH resulted in a hypercoagulable state, the 
Incidence of DVT's would be increased. Other tests of coagulation that could 
indicate an effect include PT (prothrombin time), APTT (activated partial 
thromboplastin time), platelet count, fibrinogen, antithrombin, the activation 
markers for coagulation F(1+2) and TAT (specific markers for intravascular 
thrombin formation), and the markers of fibrinolysis (D Dimer - specific marker for 
reactive degradation of cross linked fibrin), PAP (plasmin alpha2 antiplasmin -
reflects the amount of generated plasmin in the circulation) and the 
thromboelastogram (TEG) . 
Normal Haemostasis (figure 9.1) 
The physiological initiation of coagulation Is the complex of TF (tissue factor) with 
factor Vila. Minute concentrations of TF.VIIa complex initiate explosive thrombin 
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generation after a lag phase. During the lag phase, low amounts of Xa are 
generated by direct activation. This Xa activates a small amount of V, allowing the 
formation of the prothromblnase complex Xa.Va and generating low amounts of 
thrombin. This thrombin then feeds back to activate all the V to Va and all the VIII 
to Villa. Note that activation releases factor VIII from its inactive complex with 
vWF. Meanwhile, small amounts of IX have been activated to IXa by TF.VIIa., At 
this point, maximal amounts of tenase complex Vllla.lXa and. prothrombinase 
complex Xa.Va have fomned and prothrombin conversion proceeds explosively. 
TF.VII 
X IX 
TF.VIIa - XIa <- XI 
Vllla.lXa 
V 
Xa.Va 
Vlll.vWF 
Thrombin 
ProThrombin Fibrinogen Fibrin 
Solid arrows = change of state; Dotted arrows = proteolytic activation / 
deactivation; Bold = complexes 
Figure 9.1: The network of haemostasis 
85 
1 
f 
l i t 
Thromboelastogram (TEG) 
The TEG Is a graphic method of displaying the stages in the formation of a whole 
blood clot and therefore provides a visual pattern of functional clotting status*® '^^ ®®. 
It was first developed by Hartert in 1948, but remained largely a research tool until 
recently, when the search for a quick useful bed side test of coagulation coupled 
with improved computer systems, rediscovered the value of TEG. 
The TEG has as its core two mechanical parts (fig 9.2); a cuvette and a piston. 
Blood is placed In the cuvette which oscillates through 4°45' at 37° C. The piston is 
suspended in the blood sample by a torsion wire which is transduced to a chart 
recorder. When no clot exists, the motion of the pipette does not affect the piston, 
and the chart records a straight line. As strands of fibrin form they attach to the 
piston which becomes coupled to the motion of the cuvette. The transduced image 
therefore represents the shearing elasticity of the evolving blood clot. 
The TEG pattern is divided into component variables (fig 9.3). Reaction time ( r ) is 
the interval between the start of recording and the time at which the amplitude of 
the trace is 2mm. It reflects the function of the intrinsic clotting pathway and initial 
fibrin formation. Coagulation time (r and k) is the time required for the amplitude to 
reach 20mm; this provides Information on not only the Intrinsic factors but also 
platelets and fibrinogen. The clot formation rate is represented by the alpha angle. 
The maximum amplitude ( MA ) is the greatest amplitude achieved on the TEG 
and is a measure of clot strength and elasticity. 
Whole blood samples can be analysed immediately (within 4 minutes of sampling 
to prevent missing the onset of coagulation) or stored in citrate at room 
temperature and analysed between 30 and 90 minutes after re-constitution with 
calcium*®'*. Activation with celite speeds up the coagulation process. 
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Fig 9.2: Thrombelastograph® Coagulation Analyser (TEG®) 
IB m scale 
Coagulation Index: *Z.Sl 
Nonial Range: -3.6 to «3.8 
SP B X flNG HA Tm G EPL CLSe 
din Rin nin deg urn Nin d/sc X % 
3.3 a.fi L 4 7a.B 64.5 38.9 9884.5 4.B 93.8 
3-6 1-2 il-73 55-65 6111-9285 
Fig 9.3: TEG Trace 
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Literature Review 
A number of studies iiave been performed looking at the effect of haemodilution. 
The difficulty is extrapolating the results from an in vitro setting, to in vivo, to 
surgery itself and surgery In the presence haemodilution. It is this final situation 
which is clinically relevant, although the steps along the way provide valuable 
insight into the processes occurring. 
in vitro studies 
Ruttmann et aP^ (no celite activation) showed a decrease in r time and k time, 
and increase in alpha angle, with in-vltro dilution of blood using N/Saline or 
Haemaccel as compared with control. The MA increased in the saline treated 
group but remained unchanged In the Haemaccel group. They concluded that the 
changes of hypercoagulability are induced by haemodilution itself rather than the 
properties of the diluent, although saline haemodilution has a more marked effect 
on final clot strength. 
Mardel et aP^^ ^^ ° demonstrated a decrease in in-vitro clot weight and strength 
(MA) with increasing dilutions of both Haemaccel and Gelofusine, compared with 
the same dilutions with saline or Ringer's. Scanning electron microscopy showed a 
reduction in cross linkage with the colloids compared with dilution with saline, or 
controls from undiluted blood. They hypothesised that this effect could be due to 
gelatin binding to fibronectin, as demonstrated by other authors^^ '^^ "*". They 
therefore endorsed Ruttman et al's^^^ suggestion that in vivo studies need to take 
place. Unfortunately, at this stage Mardel and colleagues did not know that saline 
led to hypercoagulatlon which was therefore not a true control. It is possible that 
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the changes they observed were an increase in clot weight and strength with 
saline. Their findings will therefore not be Included in the final summary. 
Egli et al^ "** looked at the effects in vitro of hydroxyethyl starch 200 000/0.5 (HES), 
succinylated gelatin (Physiogel 4%), and 5% human albumin solution on 
coagulation. Blood samples from 96 patients were allocated randomly to one of six 
groups, to be haemodiluted to 30% or 60% by each of the 3 volume expanders. 
Blood coagulation was simultaneously assessed in native blood, after 
haemodilution with one of the above, and also after haemodilution to the same 
degree with N/Saline, with celite activation. Compared with native blood 
progressive haemodilution with any of the plasma expanders did not affect r time, 
but did increase k and decrease the alpha angle. This was significant at 30% 
haemodilution with HES, but only at 60% with the other 2. The clot strength was 
decreased in all plasma expander groups at 30% and 60% haemodilution as 
measured by a decrease in MA. Saline haemodilution resulted In a decrease in r 
and k, and increase in alpha angle at 30% haemodilution. At 60% all 3 variables 
recovered. MA decreased significantly at 60% haemodilution. They concluded that 
blood coagulation is compromised by in vitro haemodilution with all 3 plasma 
expanders. In addition, moderate haemodilution With crystalloids appeared to 
augment in vitro coagulation. In keeping with other s t u d i e s ^ T h e study by 
Ruttman et a P ^ showing a hypercoagulable state at 20% haemodilution with 
gelatin, was not observed in this study at 30% haemodilution; on the contrary, at 
60% haemodilution coagulation was impaired (prolonged r and k time, increase in 
alpha angle, decrease in MA), indicating that the degree of haemodilution may be 
crucial. 
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Petroianu et al*'*^ looked at dilutions of blood 10:2, 10:4, and 10:10 in vitro with 
varying types of gelatin solutions, dextrans and hydroxyethyl starch (HES) 
preparations. Samples were citrated and analysed within 4 hours of sampling after 
activation with celite. They found that coagulation was compromised when the 
dilution ratio of blood volume to colloid solution >10:4. Gelatin solutions had less 
effect on blood coagulation than either HES or dextran. 
Nielsen et al^"^ tested the hypothesis that haemodilution (ANH to 75%) and the 
fluid administered would adversely alter the TEG in Rabbits. Fluids used Included 
6% hetastarch In 0.9% NaCI, 5% HAS in 0.9% NaCI, balanced electrolyte solution 
containing either 6% pentastarch or 6% hetastarch. In vitro ANH resulted in a 
significant decrease in haemostatic function (increase In r time, decrease in alpha 
angle and MA), largest after ANH with albumin. The in vivo effects, in rabbits 
anaesthetised but not undergoing surgery, were that of a decrease in r time, 
increase in alpha angle and decrease In MA (accelerated clot formation with 
reduced strength) there were no significant fluid dependent effects. They 
concluded that the effects of ANH and the fluid used were markedly different 
between in vitro and in vivo ANH studies, with only the in vitro study demonstrating 
fluid specific effects. 
In vitro studies summary 
The crystalloids appear to result in hypercoagulation: N/Saline causes 
hypercoagulation (decrease in r and k, increase in alpha angle, increase in MA)^^^. 
N/Saline causes a hypercoagulable state, at 30% dilution with a decrease in r, 
decrease in k, and increase in alpha angle^'*^ However, at 60% dilution, these 
figures revert to nomnal and the MA decreases^'*^ 
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The colloids tend to result in hypocoagulation, except for this first study: 
Haemaccel causes hypercoagulation (decrease in r and k. Increase in alpha 
angle)^^^ Gelatin, HES and 5% human albumin solution cause a hypocoagulable 
state with an increase in k, decrease in alpha angle and decrease in MA at 60% 
dilution with all three, and 30% dilution with HES^'*^ Gelatin, dextrans and HES 
result in compromised coagulation when the dilution >10:4 '^* .^ Hetastarch and HAS 
result in a significant decrease in haemostatic function^**. 
An Interesting finding by Nielsen et aP"*^  was the lack of correlation between the in 
vivo and in vitro dilutional effects. In vivo they found accelerated clot formation with 
a reduced strength, drawing into question the validity of a number of the studies 
performed in vitro. 
In Vivo studies 
Ruttman et al^ "*^ administered 1000ml of either N/Saline or HES intravenously over 
30 minutes to healthy volunteers, using the native TEG for analysis. They found a 
significant reduction in fibrinogen and AT111 in both groups. In the saline group 
there was significant shortening of the r and k times, increase in alpha angle and 
MA. HES decreased the MA but did not othenwise affect the TEG. They concluded 
that haemodilution exerted a procoagulant effect. The effect with HES was offset 
by its antiplatelet action as shown by platelet aggregometry. 
The In-vivo study did not involve surgery or anaesthesia therefore lending good 
support to the argument that it Is the IV fluid itself which causes the effect. They 
confirmed that the effect was not due to acid-base or electrolyte composition of the 
diluent fluid^'*^ 
Ng et al^'*^ studied 20 patients undergoing major hepatobiliary surgery randomised 
into 2 groups; ANH (30% blood volume replacement with saline) and control. ANH 
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began after induction of anaestliesia and all samples were taken prior to the start 
of surgery. Samples were processed as whole blood (no citrate) and, not activated 
with celite. The haemodiluted group showed significant shortening of r time and k 
time, and widening of alpha angle when compared with control. AT 111 and other 
natural procoagulants and anticoagulants closely followed the haematocrit with the 
exception of TAT, indicating that a disproportionate reduction in anticoagulants is 
not the mechanism. They concluded that in vivo haemodilution with saline can 
cause a hypercoagulable state. 
In vivo studies summary 
The crystalloids again appear to result in hypercoagulation. N/Saline causes a 
decrease in r, decrease in k, increase in alpha angle, increase in MA^'*^. N/Sallne 
results in a decrease in r and k times, and increase in alpha angle^"* .^ 
The colloids again appear to cause a hypocoagulable state, although only one has 
been studied: HES causes a decrease in MA, although this decrease may be due 
to its antiplatelet action^"* .^ 
Surgery studies 
Tuman et al^''^ looked at the effect of progressive blood loss on coagulation in 87 
adults, undergoing a variety of operations, using the TEG (whole, uncitrated 
blood). Patients were given crystalloid solution as replacement for ongoing blood 
loss, with packed red cells administered if blood loss exceeded 35% estimated 
blood volume (EBV). With blood losses up to 15% EBV, TEG parameters revealed 
a hypercoagulable state (decrease in r and k, Increase in alpha angle and MA). 8 
patients had blood losses of >50% EBV. Of these, 6 showed signs of progj-essive 
hypercoagulability. The remaining 2 showed a marked reduction in MA by the time 
10 units of packed cells had been given, implying a probable deficit in platelet 
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function. Subsequent platelet transfusion resulted in dramatic improvement In the 
MA. 
Ng et aP"*^ studied 21 Chinese patients undergoing a wide variety of "general 
surgery" with an anticipated blood loss of up to 20% blood volume. Blood loss was 
replaced with N/Saline. They took samples immediately after induction and then 
every hour until the end of surgery, analysing them with the TEG without celite 
activation. They showed the progressive development of a hypercoagulable blood 
state with increasing amounts of surgical blood loss and replacement with 
N/Saline as demonstrated by shortening of the r and k times, increase in the alpha 
angle. Splitting their patients into 2 groups based on degree of blood loss, showed 
that the group with greater blood loss (therefore greater haemodilution) had 
significantly shortened r and k times and increased alpha angle. The correlation 
with blood loss and subsequent haemodilution with saline decreases the possibility 
that it is the surgical stress causing the effect. In addition, there was no further 
change in coagulation when Hb fell from 90% to 85% of pre-operative level which 
might suggest a dilutional hypocoagulable state was evolving. 
Karoutsos et al^'*^ randomised patients undergoing total hip or knee replacement 
to receive one of 3 plasma expanders to replace surgical blood loss; 3.5% 
modified gelatin solution (molecular weight 35 000 DA), 6% low molecular weight 
hydroxyethyl starch or 5% albumin solution. They showed that IV gelatin plasma 
expanders resulted in a hypercoagulable state as measured Immediately post 
surgery with the native TEG. They demonstrated a decrease in r, decrease in r+k, 
and increase in alpha angle. Interestingly, the MA (maximum amplitude) was 
normal, indicating normal clot strength. Despite these changes In the TEG, no 
clinically significant change in standard tests of haemostasis was observed. All 
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patients, fiowever, were also involved in pre-op donation, arid, cell salvage was 
used In some. 
Huttner et aP^° assessed the effects of perioperative volume replacement with 
different colloids (4% gelatine, low and medium molecular weight HES) on 
haemostasis in 60 patients undergoing major abdominal surgery. Ringer lactate 
was given to all three groups. Measurements included APTT, platelet count, 
fibrinogen, F1+2 (marker of thrombin generation), TAT 111 (marker of thrombin 
neutralisation), D-Dimer (marker of fibrin formation and degradation), vWF (marker 
of endothelial injury), platelet function. Intraoperative blood loss was approximately 
910ml to 960ml in the 3 groups. Colloid infusion volumes varied from 1880ml to 
2250ml by the time surgery was completed. They found no significant difference in 
blood loss between groups. F1+2, TAT 111, D-Dimer all Increased significantly 
during and after surgery, with no difference between groups. vWF also increased 
in all groups, showing the significantly highest increase in the gelatine treated 
group. Platelet function remained within normal range and without group 
difference. They went on to comment that In vitro studies neglect the surgical 
effect of activating coagulation, hence the discrepancies. 
Surgery studies summary 
Crystalloids lead to a hypercoagulable state "^* .^ N/Sallne leads to a decrease in r 
and k times and Increase in alpha angle, the changes correlating with the degree 
of blood loss. However no further change was seen when the Hb fell from 90% to 
85% of preoperative leveP"*^. 
Gelatin results in a hypercoagulable state with a decrease in r, decrease in r+k, 
and increase in alpha angle, with no changes seen with HES or HAS^"*^. 
Surgery activates coagulation factors^^°. 
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ANH studies 
Kramer et aP^^ performed ANH in 30 patients to a mean fiaematocrit of 25% for 
major vascular reconstruction. Venesected blood was replaced with 1.5 volumes 
of colloid and crystalloid. They noted an increase In PT from a mean of 12 to 15.5 
seconds, APTT from a mean of 30 to 60 seconds, a decrease in platelets from 250 
to 175*10^/L, and decrease in fibrinogen from 4g/L to 2g/L. All values returned to 
normal by the first post-operative day. 
Mcloughlin et aP^^ demonstrated a considerable disturbance of coagulation 
parameters (PT, APTT, FIB, PLT, coagulation factor levels) in 8 profoundly 
haemodiluted adolescents (Initial target Hb 7g/dl with 5% albumin in 0.9%Saline 
as replacement; ultimately up to 75% volume exchange) undergoing surgical 
correction of scoliosis, and 29 swine undergoing stepwise ANH until death. They 
explained the coagulopathy developing during ANH by a combined deficiency of 
coagulation factors. Interestingly platelet count was relatively spared, possibly due 
to release of platelets sequestered in the spleen. 
Olfsanger et al^^ showed no differences in PT and APTT with ANH using ringers 
lactate in patients undergoing elective TKR. 
Fukusaki et aP^^ looked at 40 patients undergoing THR, randomised into control, 
Induced hypotension, ANH, ANH plus hypotension. The first 2 groups also 
underwent pre-deposit. The 1 litre of venesected blood in the ANH group was 
replaced with HES at a ratio of 1:1. They found that ANH caused a significant 
decrease in platelet count, fibrinogen, AT111, and significant increase in APTT 
during surgery, although the changes did not appear to be clinically important. 
There were however no significant alterations In coagulation parameters in the 
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control group undergoing surgery. It is already known that HES affects 
coagulation. 
Boldt et al^^ found no perioperative alteration in platelet count, APTT, fibrinogen, 
AT111, or D Dinner in patients haemodiluted with gelatin (15ml/kg venesection) 
undergoing retropubic prostatectomy. 
Hobisch-Hagen et aP^ looked at 40 patients undergoing orthopaedic surgery, 
randomised to ANH or control. They used gelofusine at a ratio of 1:1 to replace the 
blood venesected, whilst intra-operative blood loss was replaced with a 
combination of gelofusine and Ringer's lactate. The control group underwent 
between 1 and 3 unit POD, and in both groups cell salvage was used. A mean 
(SEM) of 855 (60) ml of blood was venesected at haemodilution. In the ANH 
group, there was a significant increase in APTT immediately prior to transfusion, 
when compared with a sample taken immediately after induction; of anaesthesia 
(baseline). Fibrinogen decreased significantly during surgery in both groups, when 
compared with baseline. Platelet count decreased significantly with surgery in both 
groups. AT111 decreased significantly in both groups until transfusion, when 
compared with baseline. There was an Increase in activation markers for 
coagulation (F1+2, TAT) and fibrinolysis (DD, PAP) in both groups, with no 
difference between groups. However, all the changes shown were small. In 
addition, the control group were not a true control as POD is known to cause a 
decrease in haematocrit, essentially acting like pre-operative haemodilution. The 
addition of cell salvaged blood may have resulted in activation of coagulation not 
normally seen, although this effect would only have been seen after transfusion of 
salvaged blood. They concluded that ANH does not cause additional perioperative 
disturbances in haemostasis. 
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ANH studies summary 
Colloid and crystalloid combined results in an increase in PT, increase in APTT, 
and reduction in platelets and fibrinogen^^V The use of HAS and saline results in a 
considerable disturbance of coagulation parameters, although this was with 
profound haemodllution^^^. Ringers lactate results in no alteration in PT or APTT^''. 
Gelatin results in no alteration in platelet count, APTT, or fibrinogen^^. Although 
gelatin resulted in a significant increase in APTT, decrease in fibrinogen and 
platelet count (although these changes were seen in the control group not 
haemodlluted)^^. HES leads to a decrease in platelet count and fibrinogen, with 
an increase in APTT^^^ 
Conclusion 
So where are we left? All the changes seen are small, except for those profoundly 
haemodiluted (75%) and clinical impact is uncertain. Because of the presence of 
so many confounding factors, what is needed is a study that uses fluids in 
quantities that most readily reflect current practice. For the further understanding 
of the coagulation system, it is interesting to show that N/Saline causes a 
hypercoagulable state in vitro, however is it important? The best strategy is to 
perform a study looking at one parameter and conducting it in a prospective 
randomised fashion In order to test the hypothesis. For example, surgical patients 
could be randomised to receive only saline / Hartmann's or crystalloid / colloid and 
samples taken regularly throughout the procedure. It would answer the question 
"Is it the fluid or the dilution that matters", a point commented on by Roche and 
Ruttman^^^. It would of course be difficult to standardise transfusion, and in some 
the anaesthetists may riot be willing to avoid plasma expanders when needed. 
Some would argue that it is actual pracfice that matters, which is the basis for 
most of the above studies, and the rafionale behind our study. 
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In vitro In vivo Surgery ANH + 
Surgery 
Gelatin 
^154 
Hetastarcii/Pentastarch 
HES r 
^143 
_^149 ,1b0 
5% Albumin 
^144 
N/Saline 
| 1 3 5 
tTEG but I 
standard 
tests^^s-^ '*^ 
^ 1 4 . 
Haemaccel 
Dextran 
Ringer's lactate 
t hypercoagulation effect 
i hypocoagulation effect 
• M - no effect 
i small hypocoagulation effect 
Table 9.1: The overall effects on coagulation of intravenous fluids administered in 
vitro, in vivo, as replacement for surgical blood loss, and during surgery with ANH 
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study Performed 
Aim 
This study was designed to assess the effect of ANH on haennostasis in patients 
undergoing surgery. 
iVietl iods 
The study received approval from the Plymouth local regional ethics committee. 
Patients were recruited from a large (n=160) randomised controlled trial of ANH in 
major gastrointestinal surgery in which all patients under the care of the twelve 
participating surgeons admitted for major colorectal, gastric or pancreatic surgery 
were screened for eligibility. Recruitment commenced half way through the ANH 
study and was based on availability of the thromboelastogram. Absolute exclusion 
criteria Included Hb<11g/dl, age<18 years, and blood or blood products in the 
preceding four weeks. Exclusion criteria at the investigators and/or anaesthetists 
discretion included abnormal ECG, Ischaemic heart disease, obstructive lung 
disease, renal disease, hypertension, abnormal liver function and coagulation 
abnormality. Infonned consent was obtained and the patient remained blinded to 
treatment allocation throughout the study period. 
All patients received a standard anaesthetic comprising propofol Induction, 
isoflurane maintenance and muscle relaxation with atracurium or rocuronium. 
Antibiotic prophylaxis with cefuroxime and metronidazole was given shortly after 
induction. Epidural catheters were sited either awake or asleep depending upon 
the anaesthetist's preference. 
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Patients in tlie ANH group who received bowel preparation were given 2 litres of 
N/Sallne, which comnrienced on the day prior to surgery^^^. The volume of blood to 
be withdrawn (maximum 3 units), whilst maintaining the haemoglobin above 8g/dl, 
was calculated using a formula described by Gross^^° (figure 1). The first litre of 
venesected blood (maximum 3 units) was replaced with warmed gelofusine at a 
ratio of 1:1; the remainder replaced with warmed Hartmann's, ratio 3 or 4:1. 
Venous samples* were taken at fixed points (shown below) and analysed using 
standard laboratory tests (INR APTTR, fibrinogen, platelets) and the 
thromboelastogram. Blood loss during surgery was replaced with a combination of 
gelofusine, Hartmann's and N/Saline. The patient was monitored during the 
operation using standard equipment for the operation concerned. To maintain 
normothermia during surgery, a rewarming system (Bair Hugger), and fluid 
warmers were used. At the end of the operation, all the autologous blood was re-
transfused. If a patient required a transfusion prior to the completion of surgery, 
autologous blood was used prior to any allogeneic. At all times during the 
operation, transfusion was at the anaesthetist's discretion. 
Oropharyngeal temperature was measured at knife to skin and again at the end of 
the operation. Blood loss was estimated by swab weight, suction volumes and 
surgeon / anaesthetists estimates. 
Chemical peri-operative deep venous thrombosis prophylaxis, using 5000iu 
heparin subcutaneously, was administered after haemodilution. No patients were 
taking antiplatelet therapy. 
Blood Sample Analysis 
Samples were taken through a free flowing 14 gauge cannula, without the use of a 
tourniquet. The first 6ml were discarded, to avoid sampling activated blood^^^. 
Platelet count, APTT, PT and derived fibrinogen were measured using a standard 
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autoanalyser. TEG samples were collected In standard citrated tubes (3 mis of 
blood mixed with 0.3 mis of citrate) and stored at room temperature, a technique 
validated by Bowbrick et aP^. Samples were analysed between 30 and 90 
minutes from collection. 1ml of citrated blood was placed in a pot containing celite 
and inverted 5 times. 340 microlitres were transferred to the TEG cup using 
reverse pipetting, and mixed with 20 microlitres of 0.2 Molar Calcium chloride at 
37° Centigrade. The TEG trace was run until the maximum amplitude (MA) was 
recorded. 
Statistical Analysis 
Data was analysed within groups using the Wilcoxon signed rank test and 
between groups using Mann-Whitney. However, the measurements on the 
patients were taken through time and as such constitute a longitudinal data set. In 
particular, observations on a measurement for a given patient are likely to be 
correlated and often require special statistical models such as those describe in 
Diggle et aP^''. We used the OSWALD^^^ package to fit and verify several models, 
to broadly confirm the results of the previous two tests. 
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Sample Timing and Intervention 
ANH INTERVENTION NO ANH 
Day of admission 
2 Litres of IV N/Saline over 24 hours 
Pre GA Pre GA 
General anaesthetic 
Post GA Post GA 
ANH 
Post ANH (prior to knife to skin) 
1 Hour into surgery 
1 Hour 1 Hour 
Further surgery 
Pre re-transfusion 
Re-transfusion of autologous blood 
Post re-transfusion 
End Op End Op 
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Results 
33 patients were recruited, ANH n=17, no ANH n=16. Tfie groups were matclied 
for age, sex, weigfit, starting iiaemoglobin, duration of operation, and intra­
operative temperature (table 9.2). 3 of the 17 patients haemodiluted had less than 
3 units venesected. 
ANH (17) No ANH (16) 
Sex Male Female Male Female 
10 7 8 8 
Age (years) 63 (23-80) 66 (32-81) 
Weight (kg) 72 (14) 76 (11) 
Starting Hb (g/dl) 13.5 (1.3) 13.5 (1.3) 
Duration operation (mIn) 117(77-295) 124 (50-308) 
Blood Loss (ml) 1250-1500 (500-3750) 1000-1250 (100-3000) 
Temp start (°C) 35.6 (34.9-36.0) 35.8 (35.3-36.7) 
Temp end (°C) 35.3 (34.2-36.0) 35.6 (34.9-36.2) 
*Fluld Input (ml) 5000 (3000-9500) 4250 (2500-7000) 
Venesection Volume (ml) 1359 (780-1454) 
Patients Transfused** 7 6 
Peri-operative 
Transfusion** 
3 6 
*p=0.05 
''*Allogeneic transfusion 
Table 9.2: Illustrating groups matched 
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As operation progressed (table 9.3) there was a decrease in platelet count 
(p<0.001) and fibrinogen (p=0.001), and increase in APTTR (p=0.002) and INR 
(p=0.001). The TEG confirmed this with a decrease in alpha angle (p=0.006), MA 
(p=0.0p3) and G (p=0.001), and increase in K (p=0.008). 
PreGA PostGA 1 Hour End Op 
Angle deg 71.8 (57-80) 68.8 (39.5-
78.5)** t 
R min 
Kmin 1.3 (0.8-3.8) 1.8(0.8-5.8)** 
t 
MA mm 66 (47.5-76.5) 59.3 (42-
66.5)** t 
G d/sc 9709 (4524-
16277) 
7271 (3621-
9825) t * 
Platelets 
10^ /L 
291 (201-546) 258 (178-
493)** 
225 (164-
377)** 
186 (122-344) 
t t t 
APTTR 0.9 (0.8-1) 0.9(0.7-1.2)* 1.1 (1-1.4)** 1.3 (1-1.8)** t 
INR 1.1 (1-1.3) 1.2 (1-1.4)** 1.3 (1.1-1.8)** 
Fibrinogen g/L 3.6 (2-7) 2.7 (1.7-6)** 2.1 (1.3-3.3)* 1.8(0.9-2.2) 
t t 
P value is for comparison with previous value except for 4:=post GA to End Op 
*p<0.05 
**p<0.01 
tp=0.001 
ttP<0.001 
Table 9.3: No ANH (only results showing a significant difference included) 
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ANH (table 9.4) reduced platelet count (p=0.003) and fibrinogen (p=0.001), and 
Increased APTTR (0.003) and INR (p=0.001). R time was shortened (p=0.001) but 
there was also a decrease in MA (p=0.001) and G (p<0.001). Re-transfusion of 
autologous blood Increased platelet count (p=0.03) and fibrinogen (p=0.004), 
decreased APTTR (p=0.017) and INR (p=0.002), without affecting the TEG. 
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Pre 
GA 
Post 
GA 
Post 
ANH 
1 Hour Pre re-
transfusion 
Post re-
transfusion 
Angle deg 71 
(56.5-
80) 
67.5 
(56.5-
76.5)** 
69.3 (50-78)* 
t 
R mIn 3.9 
(2.4-
5.3) 
2.4 (1.4-
4.5) t 
3.5 (2.2-6.8)* 
t 
KmIn 1.4 (0.8-
3.9) 
1.7 (0.9-
2.7)** 
MA nnm 67.8 
(58-
78) 
60 
(22.5-
72) t 
G d/sc 10505 
(6905-
17727) 
7500 
(1451-
12857) 
t t 
Platelets 
10^ /L 
215 
(114-
477) 
154 
(111-
372)** 
•149 (101-
283)* 
154 (86-299) 164 (87-
333)* 
APTTR 0.9 
(0.7-1) 
1 (0.8-
1.3)* 
1.1 (0.8-
1.5)** 
1.3 (1.1-
1.5)* 
1.3 (1.1-2.1)* 
t 
1.1 (1-2.3)* 
INR 1 (0.9-
1.2) 
1.1 (1-
1.3)* 
1.2 (1.1-
1.6) t t 
1.5 (1.2-
1.6)* 
1.5(1.3-1.9) 
t t 
1.4 (1.2-
1.6)** 
Fibrlnoge 
ng/L 
3.3 
(1.9-
5.6) 
2.1 (1.2-
3.7) t t 
1.4 (1.1-
2.8)** 
1.6 (0.7-3.5)* 
t 
1.7 (0.8-
3.4)** 
P value is for comparison with previous value except for t=post ANH to pre 
retransfuslon 
*p<0.05; **p<0.01; tP=0.001; ttp<0.001 
Table 9.4: ANH (only results showing a significant difference included) 
106 

Between the groups (table 9.5) there was no difference in any of the variables 
measured immediately before or after the Induction of anaesthesia. At the time of 
knife to skin, the ANH group had a lower platelet count (p<0.001), increased INR 
(p=0.006), reduced MA (p=0.010) and G (p=0.011), but shortened R time 
(p=0.004). At 1 hour into operation, the platelet count remained lower (p=0.002) 
and the INR (p=0.d05) and APTTR (p=0.008) significantly prolonged. Immediately 
prior to re-transfusion the only difference was a prolonged INR (p=0.023). By the 
end of the operation there was no difference between groups. In addition there 
was no difference in estimated blood loss (table 1). 
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No ANH 
Post GA 
ANH 
Post 
ANH 
No ANH 
1 Hour 
ANH 
1 Hour 
No ANH 
End Op 
ANH 
Pre re-
transfusion 
Angle deg 72.5 
(39.5-
80.5) 
67.5 
(56.5-
76.5)* 
R mIn 4.2 (0.8-
5.3) 
2.4 (1.4-
4.5)** 
K min 
MA mm 66 (47.5-
76.5) 
60 (22.5-
72)* 
G d/sc 9709 
(4524-
16277) 
7500 
(1451-
12857)* 
Platelets 
10^ /L 
258 
(178-
493) 
154 
(111-
372) t t 
225 (164-
377) 
149 
(101-
283)** 
APTTR 0.9 (0.7-
1.2) 
1.1 (0.8-
1.5)* 
1.1 (1-1.4) 1.3 (1.1-
1.5)** 
INR 1.1 (1-
1.3) 
1.2 (1.1-
1.6)** 
1.2 (1-1.4) 1.5 (1.2-
1.6)** 
1.3 (1.1-
1.8) 
1.5 (1.3-
1.9)* 
Fibrinogen 
g/L 
*p<0.05 
**p<0.01 
tp=0.001 
ttP<0.001 
Table 9.5: Comparison between groups ANH vs. No ANH (only results showing a 
significant difference included) 
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Conclusion 
Coagulation Is significantly impaired as operation progresses. Acute 
normovolaemic haemodilution Impairs coagulation. The re-transfusion of fresh 
autologous blood improves coagulation to a similar state as patients not 
undergoing ANH. During operation, coagulation remains significantly impaired by 
ANH. 
These highly significant results suggest detailed study is now required. The fact 
the ANH study (chapter 7) showed no saving of RBC's may be due to the fact 
more were lost because of hypocoagulation. 
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Chapter 10: Thesis Summary and Conclusion 
Allogeneic transfusion does confer risk to the recipient, although these risks are 
small. The presence of an immunomodulatory effect is largely supported by 
observational studies although this is not uniform across randomised controlled 
trials. A possible explanation for the disagreement may be the effects of 
immunomoduiation are small, and the studies are underpowered. The 
implementation of universal white cell reduction will preclude the undertaking of 
further randomised controlled trials investigating the immunomodulatory effects 
mediated by allogeneic white blood cells. The risk of disease transmission is no 
doubt extremely small in developed countries; In the third world, this risk is much 
greater. The potential for transmission of vCJD remains unknown. The greatest 
real risk to the recipient remains the transfusion of "wrong blood to patient", 
although the percentage risk of transfused units is unknown. 
Allogeneic blood is likely to become scarcer with Increasing population age and 
the increased number of donors excluded. Furthermore the introduction of 
leucocyte depleted blood has led to an Increased cost pressure on health 
resources. 
Patients admitted to hospital for surgical procedures appear to understand that the 
risks of transfusion are relatively small (85% willing to have an allogeneic 
transfusion), but are largely unaware of autologous alternatives (19%). 
Gastrointestinal surgery is a high blood usage field. In our colorectal unit the 
transfusion rate between 1997 and 1999 was 43%, which correlates with other 
published data (overall transfusion rate of 56%). A personalised approach, as 
proposed by Mercuriali et al (page 29), may be of use when planning which, if any, 
blood saving technique to employ. 
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There are many methods of decreasing allogeneic transfusion, however most are 
not applicable to gastrointestinal surgery for malignancy (chapter 3). Meticulous 
surgical technique and the use of a transfusion protocol, however, represent good 
practice. The introduction of a transfusion protocol significantly decreased 
transfusion rate in our unit from 41% to 28% (page 75). Logistic regression (page 
82) demonstrated that operative blood loss was one of the three factors 
significantly affecting transfusion, the others being starting haemoglobin and age. 
Looking at our entire study population (380 patients), 29% had a starting 
haemoglobin < 12g/dl and 47% < 13g/dl. These figures imply that pre-operative 
boosting of haemoglobin may be of use In decreasing allogeneic transfusion. A 
study has subsequently been set up looking at the effect of supplemental oral 
ferrous sulphate administered at the time of diagnosis of colorectal cancer until 
admission. Erythropoietin may also be of value in this setting. 
The use of Picolax® bowel preparation causes a significant dehydrating effect 
which can be minimised by administering intravenous fluids. This Is an important 
finding as ANH involves large fluid shifts and relies on the patient being 
normovolaemic at all times. The additional use of an epidural, which amplifies the 
dehydration by expanding the intra-vascular space, may lead to increased 
instability whilst surgery is in progress, thereby triggering a transfusion when it is 
possibly not required. 
Acute normovolaemic haemodilution, so ideally suited to gastrointestinal surgery 
(page 35), does not appear to reduce transfusion rate. When compared with a 
matched historical control group, ANH significantly reduced allogeneic transfusion 
rate in our unit from 39% to 15%. However, when prospectively studied; and 
randomised, there was no reduction in transfusion rate (29% and 30%), or the 
number of units transfused (92 and 93), illustrating the problem with historical 
controls and the importance of well controlled randomised trials. The dilutional 
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effect of ANH may result In "falsely" diluted haemoglobin levels thereby triggering 
transfusion when it Is not required (page 82). It remains possible that in high blood 
loss groups, haemodilution does marginally reduce allogeneic transfusion. 
The administration of intravenous fluid affects coagulation; the result being 
dependant on the type of fluid and degree of dilution. Although the effects are 
statistically significant, the clinical implication is questionable. Why N/Saline 
causes hypercoagulation is unknown. In view of this finding, it may be prudent to 
use N/Saline rather than Hartmann's or colloid solution during resuscitation, and 
further study into this area is certainly justified. The fact that the prospective 
randomised study of ANH showed no red blood cell saving in the ANH group may 
be due to the fact more were lost in this group because of the hypocoagulation 
effect of ANH. The TEG provides valuable infomnation about the stages in 
formation of a whole blood clot. The recent improvement in the technology to 
process the information means that the TEG is gradually gaining approval, 
especially in its use differentiating between surgical bleeding and coagulopathy. 
Overall Conclusion 
This work has provided level one evidence of an absence of beneficial effect of 
acute nomnovolaemic haemodilution in major gastro-intestinal surgery. Methods to 
minimise allogeneic transfusion should be targeted at increasing pre-operative 
haemoglobin, possibly with the use of ferrous sulphate with/without erythropoietin, 
and decreasing blood loss with good surgical technique. Transfusion education 
alongside the introduction of a transfusion protocol has been shown to be 
beneficial and remains the basis of good practice. 
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Abbreviations 
ANH Acute normovolaemic haemodilution 
API 1 Activated partial thromboplastin time 
API IR Activated partial thromboplastin time ratio 
ASA American society anaesthesiologist's 
AT111 Aritithrombin 111 
EBV estimated blood volume 
EPO Erythropoietin 
F(1+2) Fragments 1 and 2 
INR International normalised ratio 
PAP plasmin alpha2 antiplasmin 
PCV Packed cell volume 
POD Pre-operative donation 
PT Prothrombin time 
RBC Red blood cell 
TAT Thrombin anti-thrombin 
TEG Thromboelastogram 
R interval between start of recording and time at which 
amplitude of trace 2mm 
K time taken from R for amplitude to reach 20mm 
a angle angle fomied by slope of TEG trace from R to K value 
MA maximum amplitude 
G derived value from MA 
TF tissue factor 
TRIM Transfusion associated immunomoduiation 
WBC White blood cell 
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Aims: B l o o d t rans fus ions a r e o f ten g iven t o surg ica l pa t ien ts . T l i i s s tudy w a s des igned t o assess w i i e t h e r acu te 
n o r m o v o l a e m i c h a e m o d i l u t i o n ( A N H ) r e d u c e s e x p o s u r e t o a l logene ic b l o o d , affects c l in ica l o u t c o m e and hosp i ta l 
s tay, a n d is feas ib le in c o l o r e c t a l su rge ry . 
Methods: A l l A S A I and 11 pat ients u n d e r g o i n g c o l e c t o m i e s p e r f o r m e d b e t w e e n 1997 a n d 1999 w e r e iden t i f ied 
r e t r o s p e c t i v e l y f r o m o u r c o l o r e c t a l c a n c e r da tabase t o asce r ta in o u r c u r r e n t pe r i and p o s t o p e r a t i v e t r ans fus ion 
p r a c t i c e . T w e n t y - s i x s e l e c t e d pat ients subsequen t l y u n d e r w e n t A N H d u r i n g c o l e c t o m y su rge ry . T h e n u m b e r o f 
pa t ien ts and uni ts t r anWused w e r e ident i f ied . 
Results: O n e h u n d r e d and t w e n t y - t h r e e o f 3 1 7 (39%) pat ien ts iden t i f ied f r o m o u r c o l o r e c t a l c a n c e r da tabase w e r e 
t r ans fused a t o t a l o f 3 2 8 un i ts (med ian 2 , range 1-7). O f t h e 2 6 pat ien ts u n d e r g o i n g A N H , 4 ( 1 5 % ) w e r e t r ans fused 
a t o ta l o f 13 uni ts (med ian 3, range 2 - 5 ) . T h e r e d u c t i o n in n u m b e r o f pat ien ts t r ans fused w a s s tat is t ica l ly s igni f icant 
(P = 0 .0 I7 ) . A N H i n c r e a s e d anaes the t i c t i m e by a m e d i a n o f 19 m i n . T h e r e w e r e n o c o m p l i c a t i o n s assoclate.d w i t h 
A N H a n d t h e m e d i a n hosp i ta l s tay w a s 9 days (range 6 - 1 3 ) . 
Conclusions: In th is p i l o t s t u d y o f s e l e c t e d pat ien ts , A N H is a feas ib le a n d ef fect ive m e t h o d o f r e d u c i n g a l l ogene i c 
b l o o d e x p o s u r e in m a j o r c o l o r e c t a l su rge ry . A p r o s p e c t i v e r a n d o m i s e d c o n t r o l l e d t r ia l is n o w urgen t l y r e q u i r e d . 
© 2 0 0 2 E l sev ie r S c i e n c e L t d . A l l r ights r e s e r v e d . 
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INTRODUCTION 
B l o o d t rans fus ions a r e o f ten g iven t o surg ica l pa t ien ts . 
A l l o g e n e i c b l o o d in th is se t t i ng con fe rs a r i sk t o t he 
r e c i p i e n t in t e r m s o f a l lerg ic r e a c t i o n , i n c reased in fec­
t i ous c o m p l i c a t i o n s , t r a n s m i s s i o n o f d isease, a l l o i m m u ­
n isa t i on a n d poss ib l y i n c r e a s e d c a n c e r r e c u r r e n c e . ' " ^ 
M o r e recen t l y , t he i n t r o d u c t i o n o f l e u c o c y t e d e p l e t e d 
b l o o d has led t o an i n c r e a s e d c o s t p r e s s u r e o n heal th 
r e s o u r c e s . ^ 
A c u t e n o r m o v o l a e m i c h a e m o d i l u t i o n ( A N H ) is an 
a u t o l o g o u s t rans fus ion t e c h n i q u e . B l o o d is v e n e s e c t e d 
f r o m a pa t ien t i m m e d i a t e l y b e f o r e o r s h o r t l y a f te r t h e 
i n d u c t i o n o f anaes thes ia a n d s imu l t aneous l y r e p l a c e d 
w i t h ce l l f r e e f lu id . By us ing th is p r o c e d u r e p r i o r t o 
i n t r a o p e r a t i v e b l o o d loss , f r esh a u t o l o g o u s b l o o d is m a d e 
avai lab le f o r la te r t r a n s f u s i o n . A s a resu l t o f h a e m o d i l u ­
t i o n b l o o d subsequen t l y l os t con ta ins p r o p o r t i o n a l l y 
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f e w e r r e d b l o o d ce l ls p e r mi l l i l i t re , t h e r e b y m in im is i ng 
loss o f a u t o l o g o u s ce l ls . 
A l t h o u g h t h e t e c h n i q u e has b e e n used in o t h e r f ie lds 
o f s u r g e r y i nc lud ing ca rd iac , * o r t h o p a e d i c , ^ urologicai,® 
h e p a t i c ' a n d vascu la r , ' ° i t has n o t b e e n r e p o r t e d in 
c o l o r e c t a l su rge ry . 
T h e a i m o f th is p i l o t s t u d y is t o assess w h e t h e r A N H 
r e d u c e s e x p o s u r e t o a l logene ic b l o o d , affects c l in ica l 
o u t c o m e and hosp i ta l s tay, a n d is feas ib le in c o l o r e c t a l 
su rge ry . 
PATIENTS AND METHODS 
T h e s t u d y r e c e i v e d a p p r o v a l f r o m t h e P l y m o u t h loca l 
reg iona l e th ics c o m m i t t e e . W e ident i f ied all A S A " 
I a n d 11 c o l o r e c t a l c a n c e r pa t ien ts o p e r a t e d o n 
b e t w e e n 1997 a n d 1999 f r o m o u r da tabase t o asce r ta in 
o u r c u r r e n t pe r i a n d p o s t o p e r a t i v e t r ans fus ion p r a c t i c e . 
A l l pa t ien ts subsequen t l y a d m i t t e d f o r m a j o r c o l o r ­
ec ta l s u r g e r y w e r e s c r e e n e d f o r h a e m o d i l u t i o n el ig ibi l i ty 
( H b > l l g / d l , A S A I o r I I ) a n d i n f o r m e d c o n s e n t 
0748-7983/02/$35.00 © 2002 Elsevier Science Ltd. All rights reserved. 
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c o h o r t o f p r i m a r y c o l o r e c t a ! t u m o u r s us ing the pu lse 
label l ing t e c h n i q u e , as r e v i e w e d e l s e v / h e r e ' D u k e s ' 
stage and pa t ien t age and g e n d e r w e r e f o u n d t o be 
stat is t ica l ly s igni f icant p r e d i c t o r s o f pa t i en t o u t c o m e m a 
mu l t i - vanab le analysis T h e lack o f a s s o c i a t i o n in th is 
s tudy b e t w e e n p ro l i f e ra t i on p a r a m e t e r s inc lud ing 
d y n a m i c i nd i ces , and su rv iva l is c o n s i s t e n t w i t h t h e 
findings in a s m a l l e r c o h o r t o f b reas t c a n c e r s s tud ied in a 
s im i la r fash ion w i t h tn vivo pu lse l abe l i ng , ' and is 
c o n s i s t e n t w i t h an ea r l i e r analys is f r o m th is cohor t . ' ' 
In VIVO dynamic p ro l i f e ra t i on ind ices a r e a resea rch 
t o o l w i t h n o i m m e d i a t e c l in ica l app l i ca t i ons . A p o p t o s i s , 
ce l l loss and ex fo l i a t i on play a s igni f icant r o l e m t h e 
v o l u m e g rov r th o f t u m o u r s in vivo P r o l i f e r a t i o n data d o 
n o t d e s c n b e th is i m p o r t a n t f e a t u r e o f t u m o u r g r o w t h , 
n o r o f o t h e r c o m p o n e n t s o f t h e b io log i ca l aggress ive­
ness o f c o l o r e c t a l c a r c i n o m a inc lud ing metas ta t i c 
po ten t ia l a n d invasive cha rac te r i s t i c s N e v e r t h e l e s s t h e 
B r d U r d / f l o w c y t o m e t r y labe l l ing t e c h n i q u e has p r o v i d e d 
va luab le and un ique i n f o r m a t i o n a b o u t t u m o u r b e h a ­
v i o u r f r o m the quant i ta t ive s t u d y o f t i m e v e c t o r e d ce i l 
p ro l i f e ra t i on p a r a m e t e r s o f c l in ica l t u m o u r s in vivo in a 
safe a n d s imp le w a y . 
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o b t a i n e d . S tanda rd p r e - o p e r a t i v e p r e p a r a t i o n i n c l u d e d 
F B C , U & E , c r o s s m a t c h o f 2 un i ts , E C G and C X R . 
F i c o l a x ' ' (Fe r r i ng Pha rmaceu t i ca l s L t d , M i d d l e s e x , U K ) 
b o w e l p r e p a r a t i o n w a s a d m i n i s t e r e d t h e day b e f o r e 
s u r g e r y . T w o l i t res o f n/sal ine w i t h 2 0 m m o l p o t a s s i u m 
w e r e a d m i n i s t e r e d o v e r I 2 h , c o m m e n c i n g in t h e 
even ing , p r i o r t o su rge ry . 
T h e v o l u m e o f b l o o d t o be w i t h d r a w n ( m a x i m u m 
3 un i ts) , w h i l s t ma in ta in ing t h e h a e m o g l o b i n a b o v e 8 g /d l , 
w a s ca lcu la ted us ing a f o r m u l a d e s c r i b e d by G r o s s 
(Fig. I). A f t e r i n d u c t i o n o f anaes thes ia , a 14 gauge 
cannu la w a s s i t ed in e i t h e r t h e e x t e r n a l jugular ve in o r a 
large f o r e a r m v e i n . E x t e n s i o n t ub i ng w i t h a t h r e e w a y 
tap a n d r u b b e r bung w a s c o n n e c t e d w h i c h a l l o w e d 
access a w a y f r o m t h e surg ica l d r a p e s . S tanda rd b l o o d 
bags con ta in i ng an t i coagu lan t c i t r a t e - p h o s p h a t e - d e x t r o s e 
( C P D ) w e r e used t o pass ive ly c o l l e c t t h e b l o o d . T h e bags 
w e r e p laced o n sca les o n t h e f l o o r a n d osc i l l a ted by 
hand d u r i n g v e n e s e c t i o n t o a l l o w a d e q u a t e m i x i n g o f 
V = E B V * ( H O - H F ) / H A V 
Ho = initial haematocrit o r H b concentration 
Hp = target haematocrit or H b concentration 
HAV = average of haematocrits o r H b concentration 
E B V = estimated blood volume (70 ml/kg man, 65 m l /Kg woman) 
F i g u r e I Formula fo r vo lume of b lood wi thdrawn. 
T a b l e I Transfusion pro toco l 
Haemoglobin >10 g/dl N o Transfusion 
Haemoglobin 8-1 Og/dl Transfuse if: 
Abnorma l E C G or , 
Ischaemic Hear t Disease or , 
Obstruct ive Lung Disease o r , 
Consultant 's Discret ion or , 
Unable t o absorb oral i ron 
Haemoglobin <8g /d l Transfuse 
an t i coagu lan t . O n c e f i l led , t h e b l o o d bag t ub i ng w a s 
c l a m p e d , t h e bag labe led a n d s t o r e d w i t h t h e pa t ien t a t 
r o o m t e m p e r a t u r e in t h e o p e r a t i n g t h e a t r e . 
W a r m e d ce l l f r ee f lu id w a s a d m i n i s t e r e d v i a a s e c o n d 
cannu la d u r i n g b l o o d w i t h d r a w a l t o ma in ta in n o r m o v o ­
laemia . T h e f i r s t l i t re o f b l o o d w i t h d r a w n w a s r e p l a c e d 
w i t h I L o f ge lo fus ine . S u b s e q u e n t b l o o d w i t h d r a w a l 
w a s r e p l a c e d w i t h H a r t m a n n ' s a t a ra t i o o f 3 o r 4 : 1 . A 
H e m o c u e B - H a e m o g l o b i n p h o t o m e t e r ( H e m o c u e L t d , 
Shef f ie ld , U K ) w a s p r e s e n t in t h e a t r e t o a l l o w n e a r 
pa t ien t h a e m o g l o b i n tes t ing . 
T h e pa t ien t w a s m o n i t o r e d d u r i n g t he o p e r a t i o n us ing 
s t a n d a r d e q u i p m e n t f o r t he o p e r a t i o n c o n c e r n e d . A t 
t h e e n d o f t h e o p e r a t i o n , all t h e a u t o l o g o u s b l o o d 
w a s re - t r ans fused . If, a t t h e anaes the t i s t ' s d i s c r e t i o n , a 
pa t ien t r e q u i r e d a t r ans fus ion p r i o r t o t h e c o m p l e t i o n 
o f su rge ry , a u t o l o g o u s b l o o d w a s used p r i o r t o any 
a l l ogene ic . 
H a e m o g l o b i n , h a e m a t o c r i t , a n d c l o t t i ng ( a P T T , I N R ) 
w e r e m e a s u r e d b e f o r e a n d a f te r h a e m o d i l u t i o n , h o u r l y 
t h r o u g h t h e p r o c e d u r e , a n d b e f o r e a n d a f te r r e t rans fus ion . 
Pat ien ts in t he h a e m o d i l u t i o n g r o u p u n d e r w e n t 
s t anda rd p o s t o p e r a t i v e c a r e i nc lud ing a d h e r e n c e t o a 
t r ans fus ion p r o t o c o l (Tab le I). P r i m a r y o u t c o m e m e a s ­
u res i nc l uded t he n u m b e r o f pat ien ts t rans fused and t h e 
n u m b e r o f uni ts t r a n s f u s e d . S e c o n d a r y o u t c o m e m e a s ­
u res i nc l uded t i m e talcen t o v e n e s e c t , c o m p l i c a t i o n s and 
length o f s tay. 
RESULTS 
O n e h u n d r e d and t w e n t y - t h r e e o f 3 1 7 (39%) A S A I and 
11 pa t ien ts o p e r a t e d o n b e t w e e n 1997 a n d 1999 w e r e 
t r ans fused a t o ta l o f 3 2 8 a l l ogene i c un i ts (med ian 2 , 
range 1-7) (Tab le 2) . B e t w e e n O c t o b e r a n d D e c e m b e r 
1999, 2 6 o f 55 (47%) pat ien ts s c r e e n e d f o r el ig ibi l i ty 
w e r e r e c r u i t e d f o r A N H . 18 ma le a n d 8 f ema le pa t ien ts 
w i t h a m e d i a n age o f 5 8 y e a r s ( range 3 4 - 7 5 ) u n d e r w e n t 
o p e r a t i o n s (Tab le 2) . F ive pat ien ts w e r e v e n e s e c t e d 
3 un i ts , t w e n t y had 2 un i ts , and o n e had o n e uni t . F o u r 
o f t h e 2 6 pat ien ts (15%) w e r e t r ans fused a t o ta l o f 13 
a l l ogene i c un i ts (med ian 3 , range 2 - 5 ) . T h e r e d u c t i o n in 
T a b l e 2 Al logeneic b lood usage in non-haemodiluted and haemodiluted patients 
Procedure Non-haemodi luted Haemodi luted 
N o . patients N o . T* (%) Tota l units N o . patients N o . T * (%) Tota l units 
Right/exit right hemicolectomy 110 4 2 (38) 97 1 0 0 
Left hemicolectomy 53 13 (25) 32 6 0 0 
An te r io r resection 119 41 (34) 123 13 3 ( 2 3 ) 11 
A P resection 31 24 (77 ) 69 4 1 (25) 2 
Subtotal colectomy 4 3 (75 ) 7 2 0 0 
Tota l 317 123 (39) 328 26 4 ( 1 5 ) 13 
* Number patients transfused (%). 
5 2 2 G. S A N D E R S ET AL 
t h e n u m b e r o f pa t ien ts t r ans fused f r o m 123 /317 (39%) 
t o 4 / 2 6 (15%) w a s stat is t ica l ly s igni f icant, P = 0 0 1 7 ( / ) 
H a e m o d i l u t i o n i n c r e a s e d anaes the t i c t ime by a m e d i a n 
o f 19 m m (range 9 - 4 0 ) T h e r e w e r e no p o s t o p e r a t i v e 
c o m p l i c a t i o n s in t h e A N H g r o u p and n o s ign i f icant 
a l t e ra t i ons in c l o t t i n g d u r i n g h a e m o d i l u t i o n T h e m e d i a n 
length o f s tay w a s 9 days (range 6 - 1 3 ) . 
DISCUSSION 
St ra teg ies f o r b l o o d c o n s e r v a t i o n inc lude m e t i c u l o u s 
surg ica l t e c h n i q u e , t rans fus ion p r o t o c o l , ' ^ e r y t h r o p o i e ­
t i n , ' ' ' h y p o t e n s i v e anaesthes ia ,^ p r e - o p e r a t i v e d o n a ­
t i o n , ' ^ ce l l s a l v a g e ' * and A N H . T h e first t w o r e p r e s e n t 
g o o d p r a c t i c e B o t h e r y t h r o p o i e t i n and h y p o t e n s i v e 
anaes thes ia have b e e n used w i t h vary ing d e g r e e s 
o f s u c c e s s bu t have n o t b e e n w i d e l y a d o p t e d 
P r e - o p e r a t i v e d o n a t i o n ( P O D ) requ i r es carefu l d o n o r 
s e l e c t i o n , v e n e s e c t i o n , adequa te s t o rage o f b l o o d and 
c o r r e c t r e - t r ans fus ion o n a t ight ly def ined t i m e sca le , 
o f ten n o t p rac t i ca l in c a n c e r s u r g e r y A l t h o u g h P O D 
has been s h o w n t o r e d u c e a l l ogene ic e x p o s u r e , t h e to ta l 
t r ans fus i on ra te is i n c r e a s e d , ' ^ t h e r e b y i nc reas ing t h e 
p robab i l i t y o f an i n c o r r e c t t r ans fus i on " In a d d i t i o n 
P O D has n o t b e e n f o u n d t o be c o s t e f f ec t i ve^ ' ' C e l l 
salvage is c u r r e n t l y n o t app l i cab le in t h e p r e s e n c e o f 
ma l ignancy o r w h e n t h e b o w e l is o p e n 
A N H has c e r t a i n advantages. T h e r e is m i n i m a l p r e ­
o p e r a t i v e p r e p a r a t i o n f o r b o t h pa t ien t and staff U n i t s 
a r e c o l l e c t e d and s t o r e d at t h e b e d s i d e i n c u r r i n g n o 
s t o r a g e and tes t i ng c o s t s , and e l im ina t ing t h e c h a n c e o f 
an i n c o r r e c t t r ans fus i on A l l uni ts c o l l e c t e d a r e r e t u r n e d 
t o t h e pat ien t , p reven t i ng was tage . S ince b l o o d is 
avai lable m t h e a t r e , pat ients can b e ' g roup a n d s a v e d ' 
a l l o w i n g a l o w e r c r o s s ma tch ra t i o 
H o w e v e r , o n l y 4 7 % o f pat ients s c r e e n e d w e r e el ig ib le 
f o r A N H . T h e ma jo r i t y w e r e e x c l u d e d b e c a u s e o f 
a n a e m i a and c o - m o r b i d d isease 
D e s p i t e t h e use o f A N H in o t h e r fields o f su rge ry , its 
benef i ts r e m a i n i nconc lus i ve "^ ' '^^ C o l o r e c t a l s u r g e r y is 
un ique in t ha t it is a high b l o o d usage field and t h e o t h e r 
a u t o l o g o u s t e c h n i q u e s a r e less app l i cab le 
In th is p i l o t s t u d y o f s e l e c t e d pat ients A N H is a 
feasib le a n d e f fec t ive m e t h o d o f r e d u c i n g a l l ogene i c 
b l o o d e x p o s u r e in m a j o r c o l o r e c t a l su rge ry A l t h o u g h 
t h e c o n t r o l g r o u p w a s m a t c h e d f o r A S A g r a d e and 
o p e r a t i o n , it r ema ins h is to r i ca l A p r o s p e c t i v e r a n d o ­
m i s e d c o n t r o l l e d t r ia l is n o w u rgen t l y r e q u i r e d 
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Randomized clinical trial of intravenous fluid replacement 
during bowel preparation for surgery 
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Background: Bowel preparation using purgatives has previously been shown significantly to increase 
haemoglobin concentration and decrease weight. Tliis prospective randomized study assessed the 
effects of administering intravenous fluid during bowel preparation. 
Methods: Patients having bowel preparation with Picolax® for colonic procedures were randomized 
prospectively to receive no intravenous fluid (group 1) or calculated intravenous crystalloid based on 
body-weight (group 2) during preparation. Physiological, haematological and biochemical variables 
were measured before and after bowel preparation. 
Results: Forty-one patients were recruited ivith a median age of 69 (range 29-86) years, 22 in group 1 
and 19 in group 2. There was no difference between groups in any of the variables measured before 
bowel preparation. On completion, there was a significant difference between groups in mean weight 
loss (P = O-Ol), postural change in systolic pressure (P = O-OIS) and serum creatinine concentration 
(P = 0-008). In addition there was a significant fall in erect blood pressure after bowel preparation in 
group 1 (P = 0-02). The mean urine output in group 1 was 982 ml and in group 2 was 1808 ml 
(P = 0-004). The faeces weight between groups was not significantly different. 
Conclusion: Picolax® bowel preparation has a significant dehydrating effect, which can be minimized by 
administering a simultaneous volume of intravenous fluid (mean 2 litres in this study). 
Paper accepted 1 June 2001 British Journal of Surgery 2001, 88, 1363-1365 
Introduction 
Two sachets of Picolax® (Ferring Pharmaceuticals, 
Langley, UK) are administered to patients for bowel 
preparation before colonic surgery in our unit. Sodium 
picosulphate is hydrolysed in the colon to reduce water and 
electrolyte absorption, while magnesium citrate acts as an 
osmotic laxative. It was our impression that a large number 
of patients receiving bowel preparation were dehydrated 
when they came to surgery. This prospective randomized 
controlled study assessed the effects of administering 
intravenous fluid duringbowel preparation. 
Patients and methods 
Patients receiving bowel preparation for colonic procedures 
were recruited. Patients in group 1 were randomized by 
sealed envelope to receive no intravenous fluid while those 
in group 2 received a calculated volume of intravenous 
normal saline duringbowel preparation, starting at the same 
©2001 Blachvell Science Ltd 
time as Picola.x® administration (intravenous infusion rate 
per h 4 ml per kg for the first 10 kg, 2 ml per kg for the 
second 10 kg then 1 ml per kg for each subsequent 
kilogram)'. Both groups received two sachets of Picolax® 
6 h apart, starting 18 h before operation, and were 
encouraged to drink imlimited clear fluids until 6 h before 
that time. The study received approval from the Plymouth 
local research ethics committee and patients were required 
to give informed consent for inclusion. 
Physiological (weight, pulse, supine and erect blood 
pressure), haematological (haemoglobin, haematocrit) and 
biochemical (sodium, potassium, urea, creatinine, urine 
osmolality) variables were measured immediately before 
starting bowel preparation and repeated 1 h before 
procedure or immediately before premedication. Weight 
was measured to the nearest 0-5 kg using a single Seca 
(Hamburg, Germany) analogue scale, which was checked 
annually by the Bristol Scales Company (Bristol, UK). Care 
was taken to ensure that the same clothing was worn at both 
weighings. Blood pressure and heart rate were measured 
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•vfixh a Dinamap Compact TS (Johnson and Johnson 
Medical, Tampa, Florida, USA). Supine readings were 
taken after lying undisturbed for 30 min. Subsequent erect 
readings were taken 2 min after sitting or standing. In 
addition, total fluid intake and output, American Society of 
Anesthesiologists (ASA) grade^ , and weight of faeces 
were recorded. Fluid intake included oral and intravenous 
fluids. 
Asamplesize of 20 in each group was calculated, based on 
finding a difference in weight between groups of 0-5 kg with 
a standard deviation of 0-55^ , power of 80 per cent and 
significance level of 0-05. Data were assessed for normality 
using the Shapiro Wilk test and subsequently analysed 
within groups and between groups using paired and 
impaired t tests as appropriate. P < 0-05 was taken as 
significant. 
Results 
Forty-one patients were recruited -wixh a median age of 69 
(range 29-86) years; there were 22 in group 1 and 19 in 
group 2. There were 26 men and 15 women. There was no 
Table 1 Change in body-weight and serum creatinine level with 
Picolax® bowel preparation 
•Creatmjn^ ^^ ^^ ^ i; - "96-5(6# >fl-8(1-.5); 
Values are mean(s.e.m.). 'P < 0-001, t P = 0009 versus initial (paired 
t test); tP = 0-01, §P = 0-008 versus group 1 (independent samples t test) 
difference between groups in baseline variables, age, sex, 
ASA grade or diagnosis before bowel preparation, and no 
evidence of non-normality in any of the variables studied. 
On completion {Tables 1 and 2), there was a significant 
difference between groups in mean weight loss (P = 0-01), 
postural change in systolic pressure (P = 0-015) and serum 
creatinine level (P = 0-008). In addition there was a 
significant change in weight within group 1 (P < 0-001), 
fell in erect systolic pressure (P = 0-011), fall in erect 
diastolic pressure (P = 0-023) and fall in supine diastolic 
pressure (P = 0-005). Serum potassium concentration 
decreased significantiy in groups 1 and 2 (P = 0-019 and 
P < 0-001 respectively) and supine pulse rate increased 
significantly in both groups (P = 0-046 and P = 0-047 
respectively). The mean difference in fluid input in the 
two groups was 2078 ml. The mean urine output in group 1 
was 982 ml and that in group 2 was 1808 ml (P = 0-004) but 
the faeces weight was not significantly different between 
groups (J'able 3). 
Discussion 
Picolax® bowel preparation has previously been shown to 
cause a significantly greater weight loss and increased 
Table 3 Fluid intake versus urine output and faecal loss 
' = ;Grou [ j j [ i ^ ^^p2 . P* 
t f i i M i ^ i ^ ^ v . 1669(254) 3747(359); < o;6pr 
- U r i n W s S p i U ' O f i i i r '982(lS9)r 1808(253) 004 • 
•>Fa|MjiWeig% 1203(182). •1183(139) n.s:. 
Values are mean(s.e.m.). 'iVIean intravenous input 2 litres, mean oral 
intake 1-7 litres. n.s.. N o t significant, 'independent samples / test 
Table 2 Blood pressure, pulse and serum potassium concentration before and after Picolax' 
Group, . ;initiai, . " -Final P' ' 
Postural jjressure di-op;(mmHg);. • i - ;^i:6(3;4).- . . :7.2(4-0) n.s. ; 
. 2 . . . . • , - H:12:9'(2-?),. \ - - --..5-7(3-1) ; n.s. i 
vErecrsystolicpre^ 1 
i42'(4); - • 
•132(6) 0011 j 
2 137(5) n.s..' 
•'Erect dastdJIcJDressi^ ^^ ^^ ^^  , • ' 1,. ;84(2)) , . • • f m 0-P23 • 
2 '. • • 84(2); 80(4): n.S; j 
.Supine diasjoiic pressure (inniHg); , 1' — . .81(2) •75(2): 0005. i 
'' i- :• ,2' * 7.9(2)^  ' 79(2) n.s. ; 
;i^otassium'(mm6W)^ • ' ' - r '•4,-4(0H), 4-1 (0-1,):- 0-019 : 
; J . . ::- '\ _•- ', • ' ^'i?4(d.i);. . - • , .4^i(0- '1) ' < 0-001 1 
Sup]ne;pulser(66^^^^ . ' ! r- . - • 77(3)-, — •'82(2)- 0046 ; 
2 . - . • 76(3),, , .•82(3) , , . 0-047 . 
Values are mean(s.e.m.). There was a significant difference in postural pressure drop between groups after Picolax® (P = 0-015, independent samples 
t test), n.s., No t significant, "paired t test 
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haemoglobin concentiation compared with a group of 
matched patients undergoing body surface surgery'. 
Patients of ASA grade 3 were noted to feel faint on standing, 
after bowel preparation. Kutt etal.'* also demonstrated an 
increase in haemoglobin concentration before barium 
enema examination. In addition there was a correlation 
benveen patients with a raised haemoglobin level and those 
experiencing headache. In a retrospective study, Lee etal.^ 
examined perioperative and postoperative fluid require­
ments in patients undergoing inpatient versus outpatient 
bowel preparation. The inpatient group was given intra­
venous fluids overnight whereas the outpatient group 
commenced intravenous fluids 1-2 h before surgery. 
Although there was a shorter length of stay in the outpatient 
group, these patients also had increased perioperative and 
postoperative fluid requirements. In a prospective rando­
mized study Lawrance etal.^ studied five different oral fluid 
regimens in 197 patients and found no difference in any of 
the groups with regard to adverse events. Hill etal.^ 
demonstrated that patients with cellular potassium deple­
tion were at risk of hypokalaemia afi:er bowel preparation 
with sodium phosphate. 
The present study confirms the dehydrating effect of 
Picolax® bowel preparation as measured by the decrease in 
weight, erect systolic, erect diastolic and supine diastolic 
pressures in group 1, and the significant difference in 
postural pressure change between groups. None of these 
variables changed significantly in group 2, indicating that 
the dehydrating effect was negated with the administration 
of intravenous saline. Interestingly, although both groups 
were encouraged to drink unlimited clear fluids during 
preparation, their oral intake was not significantly different 
(Table 3). In both groups the serum potassium concentra­
tion decreased significantly. The supine pulse rate increased 
significandy in both groups, implying a cause other than 
hypovolaemia. 
In conclusion, Picolax® bowel preparation has significant 
clinical effects, which may be particularly detrimental in 
elderly or cardiovascularly compromised patients. The 
dehydrating effects can be minimized by administering a 
simultaneous volume of intravenous fluid (mean 2 litres in 
this study). Consideration should also be given to potassium 
replacement. 
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